Endocrinology and Metabolism

Original Article

Diabetes, obesity and metabolism
Reduced Sphingosine-1-Phosphate Levels Exacerbate Type 2 Diabetes Mellitus and Associated Complications in a High-Fat Diet Mouse Model: Shih-Chang Hsu, Ching-Lu Chen, Chung Te Liu, Hung-Chieh Lo, Ying-Kuo Liu, Pei-Song Gao, Shau-Ku Huang, Chin-Wang Hsu; Endocrinol Metab. 2026;41(1):108-120. Published online August 5, 2025; DOI: https://doi.org/10.3803/EnM.2025.2360

4,261 View
111 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Type 2 diabetes mellitus (T2DM) is increasingly prevalent and frequently associated with obesity, insulin resistance, nonalcoholic fatty liver disease, and chronic kidney disease. Emerging evidence suggests sphingosine-1-phosphate (S1P), a bioactive sphingolipid, plays a significant role in the pathogenesis of T2DM. This study aimed to investigate how reduced S1P levels impact T2DM development.
Methods
S1P lyase knock-in (S1PL^C317A KI) mice, characterized by reduced S1P levels due to impaired S1P degradation, were compared with wild-type (WT) mice. Both groups were fed a high-fat diet (HFD) to induce T2DM. Parameters including body weight, insulin resistance, blood glucose levels, hepatic fat accumulation, and kidney pathology were evaluated. Next-generation sequencing was employed to identify differentially expressed genes.
Results
S1PL^C317A KI mice exhibited greater body weight, more pronounced insulin resistance, and higher blood glucose levels compared to WT mice on an HFD. Increased hepatic fat deposition and worsened diabetic kidney disease were also observed in KI mice. Sequencing analysis identified 4,656 differentially expressed genes, notably enriched in mitochondrial and bioenergetic pathways, including 133 diabetes-related genes.
Conclusion
Reduced S1P levels exacerbate T2DM symptoms, indicating that therapeutic targeting of S1P pathways may offer promising strategies for treating T2DM and its related complications.

Brief Report

Diabetes, obesity and metabolism
Causal Associations of Cardiovascular Proteins and Diabetic Nephropathy Revealed by Mediation and Phenome-Wide Mendelian Randomization: Lei Chen, Yongdi Zuo, Manrong He, Jingxue Du, Wanxin Tang; Endocrinol Metab. 2025;40(5):781-786. Published online May 19, 2025; DOI: https://doi.org/10.3803/EnM.2024.2207

3,538 View
49 Download

Abstract PDF Supplementary Material PubReader ePub: Cardiovascular factors play a critical role in the progression of diabetic nephropathy (DN). This study utilized Mendelian randomization analysis to explore the causal relationships among cardiovascular proteins, risk factors, and DN. Using cis-protein quantitative trait loci (cis-pQTL) data for 90 cardiovascular proteins, we identified C-X3-C motif chemokine ligand 1 (CX3CL1) and colony-stimulating factor-1 (CSF-1) as potential therapeutic targets for DN. CX3CL1 was found to increase DN risk through mechanisms involving body mass index, fasting insulin, and hypertension. Conversely, CSF-1 appeared to protect against DN by reducing the number of monocytes expressing high levels of human leukocyte antigen. Additionally, targeting CX3CL1 could lower the risk of DN as well as other conditions, including acute renal injury, pituitary disorders, and necrotizing vasculopathies. These results highlight CX3CL1 and CSF-1 as promising novel therapeutic targets for DN.

Review Articles

Diabetes, Obesity and Metabolism
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease: Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim; Endocrinol Metab. 2023;38(1):43-55. Published online February 27, 2023; DOI: https://doi.org/10.3803/EnM.2022.1629

26,259 View
1,471 Download
41 Web of Science
44 Crossref

Abstract PDF PubReader ePub

Chronic kidney disease (CKD) is the most common cause of end-stage renal disease in patients with type 2 diabetes mellitus (T2DM). CKD increases the risk of cardiovascular diseases; therefore, its prevention and treatment are important. The prevention of diabetic kidney disease (DKD) can be achieved through intensive glycemic control and blood pressure management. Additionally, DKD treatment aims to reduce albuminuria and improve kidney function. In patients with T2DM, renin-angiotensin-aldosterone system inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists can delay the progression of DKD. Hence, there is a need for novel treatments that can effectively suppress DKD progression. Finerenone is a first-in-class nonsteroidal mineralocorticoid receptor antagonist with clinically proven efficacy in improving albuminuria, estimated glomerular filtration rate, and risk of cardiovascular events in early and advanced DKD. Therefore, finerenone is a promising treatment option to delay DKD progression. This article reviews the mechanism of renal effects and major clinical outcomes of finerenone in DKD.

Citations

Citations to this article as recorded by

Meta-analysis of the efficacy and safety of Finerenone in diabetic kidney disease
Kai Chen, Wei Shao, Huaxiong Zhang
Medicine.2026; 105(4): e47098. CrossRef
Efficacy and Safety of Finerenone in Patients with Idiopathic Membranous Nephropathy: A Multicentre, Prospective-Retrospective Real-World Study
Jia-Yi Li, Yu-Lin Zhu, Jian-Peng Zhang, Jia-Mei Lu, Xiao-Yong Yu, Jing E, Yang Wei, Dan-Na Ma, Akhmedova Nilufar Sharipovna, Jason Choo, Chieh Suai Tan, Min Qi, Yan Li, Xiao-tao Ma, Zhe Kang, Zhao Chen, Xiang-hui Chen, Rong-Guo Fu
American Journal of Nephrology.2026; : 1. CrossRef
Finrenone and sodium-glucose cotransporter 2 inhibitor polypill: how “CONFIDENT” are we?
Gerry George Mathew
Kidney Research and Clinical Practice.2026; 45(2): 286. CrossRef
Effect of finerenone on renal function in patients with type 2 diabetic nephropathy: a retrospective cohort study
Xu-Ying Liu, Ya-Min Zhao, Ya-Guang Zhang, Yi Liu, Bo-Ya Wang, Zhen-Zhen Hao, Man-Hui Hu
Frontiers in Endocrinology.2026;[Epub] CrossRef
Kidney and Cardiovascular Protection in Diabetes: Beyond Diabetes Typology
Amy K. Mottl, Deirdre L. Sawinski, Petter Bjornstad
American Journal of Kidney Diseases.2026; 87(5): 730. CrossRef
Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease
Amy K. Mottl, Kamlesh Khunti, Chantal Mathieu
Diabetes, Obesity and Metabolism.2026; 28(5): 3568. CrossRef
Cardiovascular risk in primary aldosteronism: inflammatory drivers, residual risk, and emerging combination strategies
Haoze Liu, Zejun Wu, Xinzhe Liu, Yuyuan Hu, Kaixuan Zhang, Jiwen Shang
Frontiers in Endocrinology.2026;[Epub] CrossRef
Kidney Effects of Finerenone Added to Sodium‐Glucose Cotransporter 2 Inhibitors in Patients With Diabetic Kidney Disease
Qing Yang, Lijun Zhao, Jing Ma, Shuming Ji, Duolao Wang, Jing Li, Sheyu Li, Fang Liu
Diabetes, Obesity and Metabolism.2026; 28(7): 6225. CrossRef
Finerenone: features of action, current evidence base and examples of clinical application
A. D. Erlikh, E. V. Bublik, A. V. Zilov, O. S. Lebedeva, A. G. Farmanov, D. Y. Shchekochikhin
Diabetes mellitus.2026; 29(2): 215. CrossRef
Finerenone exposure and ischaemic stroke in patients with type 2 diabetes and chronic kidney disease: A propensity score-matched cohort study
Wu-Lung Chuang, Ruey-Hwang Chou, Yuan-Hung Wang, I-Ju Tsai, Cheng-Li Lin, Der-Yang Cho, Kuang-Hsi Chang
Clinical Medicine.2026; 26(5): 100617. CrossRef
Hyperkalemia risk with finerenone in diabetic kidney disease: a real-world analysis from the FINE-TURK cohort
Murat Özdede, Serap Yadigar, Alper Tuna Güven, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, Serpil Müge Değer, Mustafa Demir, Sümeyra Koyuncu, Üstün Yılmaz, Ayça İnci, Hülya Çolak, Bülent Demirel
Clinical Kidney Journal.2026;[Epub] CrossRef
Efficacy and safety of finerenone in adults with IgA nephropathy: a 12-month real-world study
Juan Pei, Xuejuan Sun, Xiuhua Xu, Peijin Bai, Ruihong Huang, Jun Zhang, Xing Chen, Lijing Yao, Leping Shao, Yinan Li
Renal Failure.2026;[Epub] CrossRef
Omics Studies in CKD: Diagnostic Opportunities and Therapeutic Potential
Merita Rroji, Goce Spasovski
PROTEOMICS.2025;[Epub] CrossRef
Finerenona no Tratamento da Nefropatia Diabética: Perspectivas Atuais e Evidências Clínicas
Rosana Maciel Schmidt, Luis Alberto Batista Peres, Alfredo Casagrande Laude
Cuadernos de Educación y Desarrollo.2025; 17(3): e7760. CrossRef
Role and application prospective of non-steroidal MRA in the treatment of diabetic kidney disease
Yu Sun, Mingzhu Wang
International Urology and Nephrology.2025; 57(8): 2567. CrossRef
Distinct Roles of Common Genetic Variants and Their Contributions to Diabetes: MODY and Uncontrolled T2DM
Shadi Bazzazzadehgan, Zia Shariat-Madar, Fakhri Mahdi
Biomolecules.2025; 15(3): 414. CrossRef
Renal function trajectories of Japanese adults with diabetic kidney disease on different diet therapies including energy-restricted and low-carbohydrate diets: a retrospective cohort study
Tomomi Shirai, Sakiko Inaba, Miyu Maemura, Maki Saho, Miyu Sato, Mariko Sanada, Yoko Tsukamoto, Gaku Inoue, Taichi Nagahisa, Shinichi Tanaka, Hajime Tanaka, Hideaki Kurata, Takeshi Katsuki, Toshihide Kawai, Satoru Yamada
Diabetology International.2025; 16(3): 493. CrossRef
Immune-mediated renal injury in diabetic kidney disease: from mechanisms to therapy
Lingli Ma, Dianyuan Liu, Yue Yu, Zimeng Li, Qing Wang
Frontiers in Immunology.2025;[Epub] CrossRef
Finerenone’s safety and efficacy in membranous nephropathy: an emerging perspective
Aqsa Afzal, Ayesha Fatima, Ayesha Abdul Razzaq
International Urology and Nephrology.2025; 57(10): 3479. CrossRef
A Novel Therapy of Finerenone and Dapagliflozin for Lipoprotein Glomerulopathy
Haowen Lin, Yuhe Yin, Jianchao Ma, Shuangxin Liu
Kidney International Reports.2025; 10(10): 3696. CrossRef
Intensive glycemic control and kidney disease risk: insights on hierarchical composite endpoint from a randomized clinical trial
Zhaojie Song, Haibao Xu, Jiaheng Zhang, Yezhou Liu, Chao Li, Tao Chen, Sujuan Guo, Ni Zhu
Frontiers in Medicine.2025;[Epub] CrossRef
Role of nuclear receptors, lipid metabolism, and mitochondrial function in the pathogenesis of diabetic kidney disease
Eleni Hughes, Xiaoxin X. Wang, Lily Sabol, Keely Barton, Sujit Hegde, Komuraiah Myakala, Ewa Krawczyk, Avi Rosenberg, Moshe Levi
American Journal of Physiology-Renal Physiology.2025; 329(4): F510. CrossRef
Tubular Injury in Diabetic Kidney Disease: Early Diagnosis and Intervention Strategies
Yi Lv, Chen Ye, Zixi Li, Jiajia Ye, Huanhuan Cao, Chun Zhang, Huajun Jiang, Yumei Wang
Diabetes/Metabolism Research and Reviews.2025;[Epub] CrossRef
Nephroprotective activity of naringenin in gentamicin-induced nephrotoxicity in male Wistar rats: In-vivo and in-silico evaluation
William Bwambale, Victor Otu Oka, Ekom Monday Etukudo, Daniel Udofia Owu, Etah Etah Nkanu, Idara Asuquo Okon, Saali Dembe Emmanuel, Umar Uthman Shehu, Ntoni Wilber, Allan Kambere, Richard Arinaitwe, Venesio Bwambale
Pharmacological Research - Natural Products.2025; 9: 100406. CrossRef
The nonsteroidal MR antagonist finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation
Komuraiah Myakala, Xiaoxin X. Wang, Nataliia Shults, Eleni P. Hughes, Patricia de Carvalho Ribeiro, Rozhin Penjweini, Katie Link, Keely Barton, Ewa Krawczyk, Cheryl Clarkson Paredes, Anastas Popratiloff, Jay R. Knutson, Ashley L. Cowart, Moshe Levi
American Journal of Physiology-Renal Physiology.2025; 329(5): F724. CrossRef
Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus
Xue-Dong An, Xin-Qin Li, He Zhang, Qian-You Jia, Yue-Hong Zhang, Gui-Gui Yang
World Journal of Diabetes.2025;[Epub] CrossRef
Neue Antihypertensiva im Renin-Angiotensin-Aldosteron-System
Markus van der Giet
CardioVasc.2024; 24(1): 33. CrossRef
Chicoric acid advanced PAQR3 ubiquitination to ameliorate ferroptosis in diabetes nephropathy through the relieving of the interaction between PAQR3 and P110α pathway
Weiwei Zhang, Yong Liu, Jiajun Zhou, Teng Qiu, Haitang Xie, Zhichen Pu
Clinical and Experimental Hypertension.2024;[Epub] CrossRef
Endothelial CXCR2 deficiency attenuates renal inflammation and glycocalyx shedding through NF-κB signaling in diabetic kidney disease
Siyuan Cui, Xin Chen, Jiayu Li, Wei Wang, Deqi Meng, Shenglong Zhu, Shiwei Shen
Cell Communication and Signaling.2024;[Epub] CrossRef
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
Alessio Mazzieri, Francesca Porcellati, Francesca Timio, Gianpaolo Reboldi
International Journal of Molecular Sciences.2024; 25(7): 3969. CrossRef
Rediscovery of the Implication of Albuminuria in Heart Failure: Emerging Classic Index for Cardiorenal Interaction
Kyung-Duk Min, Yuki Matsumoto, Masanori Asakura, Masaharu Ishihara
ESC Heart Failure.2024; 11(6): 3470. CrossRef
Decoding the role of aldosterone in glycation-induced diabetic complications
Mayura Apte, Saee Zambre, Pratiksha Pisar, Bishnudeo Roy, Rashmi Tupe
Biochemical and Biophysical Research Communications.2024; 721: 150107. CrossRef
Exploring the potential of finerenone in non-diabetic chronic kidney disease: a promising frontier
Ayesha Maryam, Muhammad Salman Nadeem, Ayesha Fatima, Kashaf Noor Asmat
International Urology and Nephrology.2024; 57(1): 295. CrossRef
A new perspective on proteinuria and drug therapy for diabetic kidney disease
Ruimin Zhang, Qian Wang, Yaqing Li, Qihu Li, Xuefeng Zhou, Xiangmei Chen, Zheyi Dong
Frontiers in Pharmacology.2024;[Epub] CrossRef
Molecular Therapeutics for Diabetic Kidney Disease: An Update
Man Guo, Fangfang He, Chun Zhang
International Journal of Molecular Sciences.2024; 25(18): 10051. CrossRef
Pharmacokinetic and Pharmacodynamic Interaction of Finerenone with Diltiazem, Fluconazole, and Ritonavir in Rats
Tham Thi Bui, So-Hyeon Kim, Woojin Jung, Sung-yoon Yang, Quyen Thi Tran, Hyunjung Lee, Seongwon Park, Lien Thi Ngo, Hwi-yeol Yun, Jung-woo CHAE
European Journal of Drug Metabolism and Pharmacokinetics.2024; 49(6): 701. CrossRef
A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
Shuhui Zhai, Baisheng Ma, Weiwei Chen, Qini Zhao
Frontiers in Cardiovascular Medicine.2024;[Epub] CrossRef
Exercise as a therapeutic approach to alleviate diabetic kidney disease: mechanisms, clinical evidence and potential exercise prescriptions
Rao Fan, Jianda Kong, Jiahao Zhang, Lei Zhu
Frontiers in Medicine.2024;[Epub] CrossRef
Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?
Alessio Mazzieri, Francesca Timio, Francesco Patera, Francesco Trepiccione, Mario Bonomini, Gianpaolo Reboldi
Kidney and Blood Pressure Research.2024; 49(1): 1041. CrossRef
Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease
Akshyaya Pradhan, Umesh Chandra Tripathi
The Egyptian Heart Journal.2024;[Epub] CrossRef
The Impact of Finerenone on Changes in Pulse Wave Velocity, Arterial Pressure and Heart Related Deaths in Hemodialysis Patients—Study Perspective
Ljiljana Fodor Duric, Bozidar Vujicic, Tonko Gulin, Matko Gulin
Open Journal of Nephrology.2024; 14(02): 216. CrossRef
Epigenetic modification in diabetic kidney disease
Zhe Liu, Jiahui Liu, Wanning Wang, Xingna An, Ling Luo, Dehai Yu, Weixia Sun
Frontiers in Endocrinology.2023;[Epub] CrossRef
Novel Approaches in Chronic Renal Failure without Renal Replacement Therapy: A Review
Sandra Martínez-Hernández, Martín Muñoz-Ortega, Manuel Ávila-Blanco, Mariana Medina-Pizaño, Javier Ventura-Juárez
Biomedicines.2023; 11(10): 2828. CrossRef
Finerenone and other future therapeutic options for Alport syndrome
Helen Pearce, Holly Mabillard
Journal of Rare Diseases.2023;[Epub] CrossRef

Diabetes, Obesity and Metabolism
Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?: Eun-Jung Rhee; Endocrinol Metab. 2022;37(3):415-429. Published online June 29, 2022; DOI: https://doi.org/10.3803/EnM.2022.304

11,395 View
359 Download
5 Web of Science
5 Crossref

Abstract PDF PubReader ePub

The world is suffering from a rapid increase in the number of people with diabetes due to the increased prevalence of obesity and lengthened life span. Since the development of insulin thanks to the efforts of Prof. Banting and Dr. Best in 1922, for which they won the Nobel Prize, remarkable developments in anti-diabetic medications have dramatically lengthened the lifespan of patients with diabetes. However, the control rate of hyperglycemia in patients with diabetes remains unsatisfactory, since glycemic control requires both medication and lifestyle modifications to slow the deterioration of pancreatic beta-cell function and prevent diabetic complications. From the initial “triumvirate” to the “ominous octet,” and now the “egregious eleven,” the number of organs recognized as being involved in hyperglycemia and diabetes has increased with the development of anti-diabetic medications. Recent unexpected results from outcome trials of anti-diabetic medications have enabled anti-diabetic medications to be indicated for the prevention of chronic kidney disease and heart failure, even in patients without diabetes. In this review, I would like to summarize the extra-glycemic effects of anti-diabetic medications.

Citations

Citations to this article as recorded by

Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases
Snehal Raut, Luca Cucullo
Antioxidants.2025; 14(12): 1490. CrossRef
Spectrum of effects of dipeptidyl peptidase-4 inhibitors: within and beyond glycemic control (part 2)
L. A. Ruyatkina, D. S. Ruyatkin
Diabetes mellitus.2025; 28(5): 451. CrossRef
Association between underweight and risk of heart failure in diabetes patients
Tae Kyung Yoo, Kyung‐Do Han, Eun‐Jung Rhee, Won‐Young Lee
Journal of Cachexia, Sarcopenia and Muscle.2024; 15(2): 671. CrossRef
Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Diabetes & Metabolism Journal.2024; 48(1): 83. CrossRef
To do one and to get more: Part I. Diabetes and bone
Wen-Ling Lee, Peng-Hui Wang, Szu-Ting Yang, Chia-Hao Liu, Wen-Hsun Chang, Fa-Kung Lee
Journal of the Chinese Medical Association.2022; 85(10): 965. CrossRef

Original Articles

Diabetes, Obesity and Metabolism
Short-Chain Fatty Acids Attenuate Renal Fibrosis and Enhance Autophagy of Renal Tubular Cells in Diabetic Mice Through the HDAC2/ULK1 Axis: Xiaoying Ma, Qiong Wang; Endocrinol Metab. 2022;37(3):432-443. Published online May 16, 2022; DOI: https://doi.org/10.3803/EnM.2021.1336

13,405 View
203 Download
35 Web of Science
37 Crossref

Abstract PDF PubReader ePub

Background
This study investigated the effect of short-chain fatty acids (SCFAs) on diabetes in a mouse model.
Methods
Autophagy in Akita mice and streptozocin (STZ)-induced diabetic C57BL/6 mice was determined by Western blots and immunohistochemistry (IHC). Western blots, IHC, hematoxylin and eosin staining, Masson staining, periodic acid-Schiff staining, and picrosirius red staining were conducted to detect whether autophagy and renal function improved in Akita mice and STZ-induced diabetic C57BL/6 mice after treatment of SCFAs. Western blots, IHC, and chromatin immunoprecipitation were performed to determine whether SCFAs affected diabetic mice via the histone deacetylase (HDAC2)/unc-51 like autophagy activating kinase 1 (ULK1) axis. Diabetic mice with kidney-specific knockout of HDAC2 were constructed, and IHC, Masson staining, and Western blots were carried out to detect whether the deletion of endogenous HDAC2 contributed to the improvement of autophagy and renal fibrosis in diabetic mice.
Results
Reduced autophagy and severe fibrosis were observed in Akita mice and STZ-induced diabetic C57BL/6 mice. Increased autophagy and reduced renal cell fibrosis were found in SCFA-treated Akita diabetic mice and STZ-induced diabetic C57BL/6 mice. Diabetic mice treated with SCFAs had lower HDAC2 expression and more enriched binding of ULK1 promoter sequences to H3K27Ac. Endogenous knockout of HDAC2 caused enhanced autophagy and decreased renal fibrosis in diabetic mice treated with SCFAs.
Conclusion
SCFAs enhanced autophagy of renal tubular cells and attenuated renal fibrosis in diabetic mice through the HDAC2/ULK1 axis.

Citations

Citations to this article as recorded by

Microbiome dynamics in attention-deficit hyperactivity disorder: A systematic review and meta-analysis decoding the role of gut dysbiosis and potential dietary interventions
Sourav Ghosh, Shelly Singh
European Child & Adolescent Psychiatry.2026; 35(1): 31. CrossRef
Weizmannia coagulans BC99 alleviates pediatric allergic rhinitis via the gut microbiota-SCFAs- immunomodulatory axis: A randomized, double-blind, placebo-controlled trial
Zhidong Han, Huanhuan Zhu, Yuna Yang, Yibo Wang, Xuan Li, Jianguo Zhu, Ying Wu, Shuguang Fang, Shaobin Gu
International Immunopharmacology.2026; 168: 115787. CrossRef
Bridging gut microbiota and renal health: Klotho as a promising therapeutic agent in DKD
Pratik Shankar Rakshe, Anil Bhanudas Gaikwad
Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(5): 6325. CrossRef
USP47 stabilizes HDAC2 to ameliorate cigarette smoke-induced skeletal muscle atrophy by suppressing CYP1A1/ROS-mediated autophagy
Chao Li, MingZhi Ou, GuiXian Zheng, Gang Jiang, Xiao Hu, YongLiang Jiang
Free Radical Biology and Medicine.2026; 246: 107. CrossRef
Butirat Supplementation and Epigenetic Modulation via Histon Deacetylase Inhibition in Type 2 Diabetes: A Narrative Review with Perspectives for Indonesia
Aliza Salsabila Ainaputri , Ahsanal Kasasiah, Jekmal Malau , Cantika Aprillia , Dewi Pratiwi Purba Siboro , Endeh Apriyanti , Afif Tri Nugraha
Journal of Pharmaceutical and Sciences.2026; : 407. CrossRef
Beyond hyperglycemia: histone modification-mediated epigenetic dysregulation in diabetic retinopathy and nephropathy
Minxuan Tang, Hongyu Zhu, Suyan Li, Lei Qiao
Diabetology & Metabolic Syndrome.2026;[Epub] CrossRef
Research Progress on the Mechanisms of Gut Microbiota-Derived Metabolites Mediating the Progression of Chronic Kidney Disease and Therapeutic Strategies
毓轲徐
Advances in Clinical Medicine.2026; 16(03): 1069. CrossRef
Shenqinlong Qingfei Peiyuan Keli alleviates inflammation, macrophage autophagy and M1 polarization via inhibiting HDAC2-mediated ULK1 deacetylation in pneumococcal pneumonia
Xiyuan Song, Pengfei Meng, Runze Guo, Xiuxia Ma, Feng Sang, Liran Xu
Letters in Drug Design & Discovery.2026; 23(3): 100369. CrossRef
The gut-kidney axis revisited: Integrating gut microbiota, autophagy and metabolomics in chronic kidney disease
Khemender Lidoo, Rupinder Kaur, Ravinder Singh, Sarita Jangra, Thakur Gurjeet Singh, Pratima Kumari
International Immunopharmacology.2026; 187: 117238. CrossRef
Propionic Acid Remodels Mitochondrial Metabolism in SH-SY5Y Cells
Caitlyn Mahony, Erin Buchanan, Colleen O’Ryan
Biology.2026; 15(16): 1424. CrossRef
Microbiota-associated metabolic networks in gut-kidney communication and renal immune regulation: mechanisms and therapeutic potential
Hongkun Zhang, Tao Zhang, Zhengchao Pan, Yue Zhang, Tingting Liang, Haijian Liu, Baisen Wang, Yongduo Yu, Shengzhi Wang
Frontiers in Microbiology.2026;[Epub] CrossRef
Histone deacetylases and their inhibitors in kidney diseases
Yue Zheng, Tie-Ning Zhang, Peng-Hui Hao, Ni Yang, Yue Du
Molecular Therapy.2025; 33(8): 3485. CrossRef
Chidamide, a novel histone deacetylase inhibitor, alleviates renal fibrosis by suppressing the PI3K/AKT signaling pathway
Yumei Liu, Liwen Mao, Yanbing Tang, Xiaowen Huang, Cunjin Su, Ye Zhu, Qianqian Duan, Kai Song, Jie Pan, Zhanhong Hu
Biochemical Pharmacology.2025; 240: 117098. CrossRef
Contribution of histone deacetylases (HDACs) to the regulation of histone and non-histone proteins: implications for fibrotic diseases
Sunyoung Jang, Nayun Choi, Jong Hoon Park, Kyung Hyun Yoo
BMB Reports.2025; 58(8): 313. CrossRef
Gut Microbiota and Its Metabolites Modulate Pregnancy Outcomes by Regulating Placental Autophagy and Ferroptosis
Xingyu Du, Mabrouk Elsabagh, Feiyang He, Huisi Wu, Bei Zhang, Kewei Fan, Mengzhi Wang, Hao Zhang
Antioxidants.2025; 14(8): 970. CrossRef
Sea Cucumber Egg Oligopeptides Ameliorate Cognitive Impairments and Pathology of Alzheimer’s Disease Through Regulating HDAC3 and BDNF/NT3 via the Microbiota–Gut–Brain Axis
Guifeng Zhang, Yanjie Dou, Huiwen Xie, Dan Pu, Longxing Wang, Renjun Wang, Xiaofei Han
Nutrients.2025; 17(14): 2312. CrossRef
Programmed Cell Death in Diabetic Kidney Disease: Mechanisms and Therapeutic Targeting
Shanshan Tang, Yuting Sun, Wenjie Sun, Xiaomin Kang, Xuefei Zhao, Linlin Jiang, Qing Gao, Xuedong An, Hangyu Ji, Fengmei Lian
Journal of Inflammation Research.2025; Volume 18: 13001. CrossRef
Analysis of the potential mechanism of stem cells in the treatment of diabetic nephropathy based on 16S, metabolome and transcriptome
Xing-na Liao, Li-lan Huang, Ji Yang, Yue-yuan Hou, Yi-xiao Quan, Yi-hua Bai
Genomics.2025; 117(6): 111113. CrossRef
The Gut–Kidney Dialogue: Unraveling the Microbial Symphony in Renal Fibrosis
Zi‐Hui Mao, Yong Liu, Shaokang Pan, Qing Zhang, Yingjin Qiao, Xiaoya Zhang, Duopin Li, Jingfang Chen, Dongwei Liu, Qi Feng, Zhangsuo Liu
The FASEB Journal.2025;[Epub] CrossRef
Crosstalk between acetylation modification and autophagy in cancer: roles, mechanisms, and therapeutic potential
Yingnan Liu, Ziwei Yan, Zhanqi Fu, Xiaoyang Wu, Fang Wang, Yuan Yuan
Cell Death Discovery.2025;[Epub] CrossRef
Microbial short chain fatty acids: Effective histone deacetylase inhibitors in immune regulation (Review)
Jing Wang, Qin Zhao, Shuwan Zhang, Jia Liu, Xingyue Fan, Bin Han, Yaqin Hou, Xiaopeng Ai
International Journal of Molecular Medicine.2025; 57(1): 1. CrossRef
Recent advances and potentiality of postbiotics in the food industry: Composition, inactivation methods, current applications in metabolic syndrome, and future trends
Yujie Zhong, Tao Wang, Ruilin Luo, Jiayu Liu, Ruyi Jin, Xiaoli Peng
Critical Reviews in Food Science and Nutrition.2024; 64(17): 5768. CrossRef
NSD1 supports cell growth and regulates autophagy in HPV-negative head and neck squamous cell carcinoma
Iuliia Topchu, Igor Bychkov, Demirkan Gursel, Petr Makhov, Yanis Boumber
Cell Death Discovery.2024;[Epub] CrossRef
Dietary fiber intake and its association with diabetic kidney disease in American adults with diabetes: A cross-sectional study
Xin-Hua Jia, Sheng-Yan Wang, Ai-Qin Sun
World Journal of Diabetes.2024; 15(3): 475. CrossRef
Role of Histone Modifications in Kidney Fibrosis
Shengyu Pan, Tianhui Yuan, Yuqi Xia, Weimin Yu, Xiangjun Zhou, Fan Cheng
Medicina.2024; 60(6): 888. CrossRef
ULK1 as a therapeutic target in kidney diseases: Current perspective
Shruti Shreya, Neha Dagar, Vishwadeep Shelke, Bhupendra Puri, Anil Bhanudas Gaikwad
Expert Opinion on Therapeutic Targets.2024; 28(10): 911. CrossRef
Role of Epigenetic Changes in the Pathophysiology of Diabetic Kidney Disease
Marita Liebisch, Gunter Wolf
Glomerular Diseases.2024; 4(1): 211. CrossRef
N-acetyltransferase 10 regulates UNC-51-like kinase 1 to reduce tubular cell injury and kidney stone formation
Le Wang, Jinjing Huang, Lei Song, Ben Ke
Cytojournal.2024; 21: 68. CrossRef
Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets
Feng Shu, Han Xiao, Qiu-Nuo Li, Xiao-Shuai Ren, Zhi-Gang Liu, Bo-Wen Hu, Hong-Sheng Wang, Hao Wang, Guan-Min Jiang
Signal Transduction and Targeted Therapy.2023;[Epub] CrossRef
Mechanisms of Blood–Brain Barrier Protection by Microbiota-Derived Short-Chain Fatty Acids
Ekaterina Fock, Rimma Parnova
Cells.2023; 12(4): 657. CrossRef
The Role of Histone Modifications in the Pathogenesis of Diabetic Kidney Disease
Christodoula Kourtidou, Konstantinos Tziomalos
International Journal of Molecular Sciences.2023; 24(6): 6007. CrossRef
Mechanism of histone deacetylase HDAC2 in FOXO3-mediated trophoblast pyroptosis in preeclampsia
Jia Liu, Weihui Yang
Functional & Integrative Genomics.2023;[Epub] CrossRef
Macrophage polarization induces endothelium-to-myofibroblast transition in chronic allograft dysfunction
Zeping Gui, Xiang Zhang, Qianguang Han, Zhou Hang, Ruoyun Tan, Min Gu, Zijie Wang
Renal Failure.2023;[Epub] CrossRef
Periodic acid–Schiff staining in oral exfoliative cytology of diabetic patients: The odyssey for noninvasive screening – A systematic review and meta-analysis
K. Yesoda Aniyan, Krithika Chandrasekar Lakshmi, Anuradha Ganesan
Dental Research Journal.2023;[Epub] CrossRef
Luteolin alleviates renal ischemia-reperfusion injury in streptozotocin induced diabetic rats by inhibiting metalloenzymes expression
Rakesh B. Daude, Jigna S. Shah
Current Issues in Pharmacy and Medical Sciences.2023; 36(4): 199. CrossRef
Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression
Jiayu Wang, Jiaxing Li, Xin Zhang, Min Zhang, Xiaopeng Hu, Hang Yin
Frontiers in Molecular Biosciences.2022;[Epub] CrossRef
Sacubitril/Valsartan contributes to improving the diabetic kidney disease and regulating the gut microbiota in mice
Peipei Wang, Ruixue Guo, Xiwen Bai, Wen Cui, Yiding Zhang, Huangmin Li, Jin Shang, Zhanzheng Zhao
Frontiers in Endocrinology.2022;[Epub] CrossRef

Mineral, Bone & Muscle Big Data Articles (National Health Insurance Service Database)
Hip Fracture Risk According to Diabetic Kidney Disease Phenotype in a Korean Population: Seung Eun Lee, Juhwan Yoo, Kyoung-Ah Kim, Kyungdo Han, Han Seok Choi; Endocrinol Metab. 2022;37(1):148-158. Published online February 28, 2022; DOI: https://doi.org/10.3803/EnM.2021.1315

8,870 View
151 Download
9 Web of Science
10 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Diabetic kidney disease (DKD) is associated with an elevated risk of fractures. However, little is known about the association between proteinuric or non-proteinuric DKD and the risk of hip fracture. Thus, we investigated the incidence of hip fractures among Korean adults with type 2 diabetes mellitus (T2DM) stratified by DKD phenotype.
Methods
In this retrospective cohort study using the Korean National Health Insurance Service database, patients with T2DM who received at least one general health checkup between 2009 and 2012 were followed until the date of hip fracture, death, or December 31, 2018. We classified the DKD phenotype by proteinuria and estimated glomerular filtration rate (eGFR), as follows: no DKD (PU⁻GFR⁻), proteinuric DKD with normal eGFR (PU⁺GFR⁻), non-proteinuric DKD with reduced eGFR (PU⁻GFR⁺), and proteinuric DKD with reduced eGFR (PU⁺GFR⁺)
Results
The cumulative incidence of hip fractures was highest in the PU⁺GFR⁺ group, followed by the PU⁻GFR⁺ group and the PU⁺GFR⁻ group. After adjustment for confounding factors, the hazard ratio (HR) for hip fracture was still highest in the PU⁺GFR⁺ group. However, the PU⁺GFR⁻ group had a higher HR for hip fracture than the PU⁻GFR⁺ group (PU⁺GFR⁺ : HR, 1.69; 95% confidence interval [CI], 1.57 to 1.81; PU⁺GFR⁻ : HR, 1.37; 95% CI, 1.30 to 1.46; PU⁻GFR⁺ : HR, 1.20; 95% CI, 1.16 to 1.24 using the PU⁻GFR⁻ group as the reference category).
Conclusion
The present study demonstrated that DKD was significantly associated with a higher risk of hip fracture, with proteinuria as a major determinant.

Citations

Citations to this article as recorded by

Bone Mineral Density and the Risk of Fracture According to eGFR in Postmenopausal Women
Minsang Kim, Kyungdo Han, Jin Kyung Kwon, Jae-ik Oh, Jinsun Lee, Jung Hun Koh, Min Woo Kang, Jeong Min Cho, Semin Cho, Seong Geun Kim, Sehyun Jung, Hyuk Huh, Soojin Lee, Eunjeong Kang, Yaerim Kim, Kwon Wook Joo, Dong Ki Kim, Sehoon Park
Journal of the American Society of Nephrology.2026; 37(5): 984. CrossRef
Diabetes progression and its association with fracture risk in type 2 diabetes
Bongsung Kim, Kyu-Na Lee, Kyungdo Han, Mee Kyoung Kim
Osteoporosis International.2026;[Epub] CrossRef
Real‐world risk factors and clinical implications of early estimated glomerular filtration rate decline after sodium‐glucose cotransporter‐2 inhibitor therapy
Jangwook Lee, Dayoung Kang, Kyoung‐Ah Kim, Han Seok Choi, Soomin Jo, Joeun Kim, Jae Yoon Park, Seung Eun Lee
Journal of Diabetes Investigation.2026;[Epub] CrossRef
Associations Between Renal Dysfunction Subtypes and Vertebral Fracture in Patients with Type 2 Diabetes: A Longitudinal Study
Nandong Hu, Yiping Zhang, Zicheng Wei, Rui Yu, Yingying Zhang, Xiao Chen
Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 1915. CrossRef
Risk of fracture with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: an updated meta-analysis of randomized controlled trials
Mahdieh Khoshzaban Banisi
International Journal of Physiology, Pathophysiology and Pharmacology.2025; 17(3): 61. CrossRef
Proteinuria screening and risk of bone fracture: a retrospective cohort study using a nationwide population-based database
Akira Okada, Akira Honda, Hideaki Watanabe, Yusuke Sasabuchi, Shotaro Aso, Kayo Ikeda Kurakawa, Masaomi Nangaku, Toshimasa Yamauchi, Hideo Yasunaga, Hirotaka Chikuda, Takashi Kadowaki, Satoko Yamaguchi
Clinical Kidney Journal.2024;[Epub] CrossRef
Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong
David Tak Wai Lui, Tingting Wu, Eric Ho Man Tang, Ivan Chi Ho Au, Chi Ho Lee, Yu Cho Woo, Kathryn Choon Beng Tan, Carlos King Ho Wong
Diabetes Research and Clinical Practice.2023; 197: 110576. CrossRef
Diagnose und Management der Osteoporose bei Diabetes mellitus (Update 2023)
Christian Muschitz, Alexandra Kautzky-Willer, Yvonne Winhofer, Martina Rauner, Judith Haschka, Daniel Cejka, Robert Wakolbinger-Habel, Peter Pietschmann
Wiener klinische Wochenschrift.2023; 135(S1): 207. CrossRef
Association between exercise and risk of fractures in new-onset type 2 diabetes: a retrospective cohort study
Seung Eun Lee, Juhwan Yoo, Bong-Seong Kim, Kyoung-Ah Kim, Kyungdo Han, Han Seok Choi
Archives of Osteoporosis.2023;[Epub] CrossRef
Two-Year Changes in Diabetic Kidney Disease Phenotype and the Risk of Heart Failure: A Nationwide Population-Based Study in Korea
Seung Eun Lee, Juhwan Yoo, Han Seok Choi, Kyungdo Han, Kyoung-Ah Kim
Diabetes & Metabolism Journal.2023; 47(4): 523. CrossRef

Diabetes, Obesity and Metabolism
EW-7197 Attenuates the Progression of Diabetic Nephropathy in db/db Mice through Suppression of Fibrogenesis and Inflammation: Kyung Bong Ha, Weerapon Sangartit, Ah Reum Jeong, Eun Soo Lee, Hong Min Kim, Soyeon Shim, Upa Kukongviriyapan, Dae-Kee Kim, Eun Young Lee, Choon Hee Chung; Endocrinol Metab. 2022;37(1):96-111. Published online February 28, 2022; DOI: https://doi.org/10.3803/EnM.2021.1305

10,645 View
253 Download
13 Web of Science
11 Crossref

Abstract PDF PubReader ePub

Background
Diabetic nephropathy (DN) is characterized by albuminuria and accumulation of extracellular matrix (ECM) in kidney. Transforming growth factor-β (TGF-β) plays a central role in promoting ECM accumulation. We aimed to examine the effects of EW-7197, an inhibitor of TGF-β type 1 receptor kinase (ALK5), in retarding the progression of DN, both in vivo, using a diabetic mouse model (db/db mice), and in vitro, in podocytes and mesangial cells.
Methods
In vivo study: 8-week-old db/db mice were orally administered EW-7197 at a dose of 5 or 20 mg/kg/day for 10 weeks. Metabolic parameters and renal function were monitored. Glomerular histomorphology and renal protein expression were evaluated by histochemical staining and Western blot analyses, respectively. In vitro study: DN was induced by high glucose (30 mM) in podocytes and TGF-β (2 ng/mL) in mesangial cells. Cells were treated with EW-7197 (500 nM) for 24 hours and the mechanism associated with the attenuation of DN was investigated.
Results
Enhanced albuminuria and glomerular morphohistological changes were observed in db/db compared to that of the nondiabetic (db/m) mice. These alterations were associated with the activation of the TGF-β signaling pathway. Treatment with EW-7197 significantly inhibited TGF-β signaling, inflammation, apoptosis, reactive oxygen species, and endoplasmic reticulum stress in diabetic mice and renal cells.
Conclusion
EW-7197 exhibits renoprotective effect in DN. EW-7197 alleviates renal fibrosis and inflammation in diabetes by inhibiting downstream TGF-β signaling, thereby retarding the progression of DN. Our study supports EW-7197 as a therapeutically beneficial compound to treat DN.

Citations

Citations to this article as recorded by

Mosla chinensis Maxim extracts exert anti-inflammatory, antioxidant, and antifibrotic effects in silicosis
Shao-Tung Wu, Cheng-Wei Huang, Tsung-Han Lee, Hui-Chun Ku
Journal of Ethnopharmacology.2026; 358: 121047. CrossRef
Abrine targets ERK to suppress EMT and lung metastasis model via MAPKs and Nrf2/Keap-1/HO-1 signaling
Yufang Shen, Linyu Xiao, Lina Liu, Lianting Liao, Xianmin Zou, Pengfei Shen, Jinlong Zhao, Renyikun Yuan, Hongwei Gao, Chun Yao
Frontiers in Immunology.2026;[Epub] CrossRef
Endoplasmic reticulum stress as a driver and therapeutic target for kidney disease
Jae Hyun Byun, Paul F. Lebeau, Jackie Trink, Nikhil Uppal, Matthew B. Lanktree, Joan C. Krepinsky, Richard C. Austin
Nature Reviews Nephrology.2025; 21(5): 299. CrossRef
Targeting endoplasmic reticulum stress: an innovative therapeutic strategy for podocyte-related kidney diseases
Jiao Lv, Honghai Yu, Sasa Du, Pengyu Xu, Yunyun Zhao, Wenxiu Qi, Xiuge Wang
Journal of Translational Medicine.2025;[Epub] CrossRef
Evaluation of the novel ALK5 inhibitor EW-7197 on therapeutic efficacy in renal fibrosis using a three-dimensional chip model
So Young Jang, Seong-Hye Hwang, Yunyeong Choi, Wan-Young Kim, Sung Hyuk Park, Won Mook Kim, Eun-Jeong Kwon, Sejoong Kim
Kidney Research and Clinical Practice.2025; 44(4): 612. CrossRef
Combination of THU/ALK-5i exhibits profound anti-MASH activity through suppression of lipogenesis and fibrogenesis
Kampeebhorn Boonloh, Eun Soo Lee, Su Ho Jo, Na Won Park, So Bin Lee, Choon Hee Chung
Scientific Reports.2025;[Epub] CrossRef
CD163 and TYROBP Are Two Therapeutic Targets for Hyperglycemia‐Induced Mesangial Cell Stress
Zhang Ran, Zhang Guiling, Fan Yanna, Luo Laimin
Chemical Biology & Drug Design.2025;[Epub] CrossRef
TGF-β signaling in health, disease and therapeutics
Ziqin Deng, Tao Fan, Chu Xiao, He Tian, Yujia Zheng, Chunxiang Li, Jie He
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Endoplasmic Reticulum Stress-Mediated Cell Death in Renal Fibrosis
Shangze Guo, Yinghao Tong, Ting Li, Kexin Yang, Wei Gao, Fujun Peng, Xiangyu Zou
Biomolecules.2024; 14(8): 919. CrossRef
Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols
Qi Jin, Tongtong Liu, Yuan Qiao, Donghai Liu, Liping Yang, Huimin Mao, Fang Ma, Yuyang Wang, Liang Peng, Yongli Zhan
Frontiers in Immunology.2023;[Epub] CrossRef
Beneficial Effects of a Curcumin Derivative and Transforming Growth Factor-β Receptor I Inhibitor Combination on Nonalcoholic Steatohepatitis
Kyung Bong Ha, Eun Soo Lee, Na Won Park, Su Ho Jo, Soyeon Shim, Dae-Kee Kim, Chan Mug Ahn, Choon Hee Chung
Diabetes & Metabolism Journal.2023; 47(4): 500. CrossRef

Diabetes, Obesity and Metabolism
Tetrahydrocurcumin Ameliorates Kidney Injury and High Systolic Blood Pressure in High-Fat Diet-Induced Type 2 Diabetic Mice: Weerapon Sangartit, Kyung Bong Ha, Eun Soo Lee, Hong Min Kim, Upa Kukongviriyapan, Eun Young Lee, Choon Hee Chung; Endocrinol Metab. 2021;36(4):810-822. Published online August 27, 2021; DOI: https://doi.org/10.3803/EnM.2021.988

9,374 View
200 Download
15 Web of Science
15 Crossref

Abstract PDF PubReader ePub

Background
Activation of the intrarenal renin-angiotensin system (RAS) is implicated in the pathogenesis of kidney injury and hypertension. We aimed to investigate the protective effect of tetrahydrocurcumin (THU) on intrarenal RAS expression, kidney injury, and systolic blood pressure (SBP) in high-fat diet (HFD)-induced type 2 diabetic mice.
Methods
Eight-week-old male mice were fed a regular diet (RD) or HFD for 12 weeks, and THU (50 or 100 mg/kg/day) was intragastrically administered with HFD. Physiological and metabolic changes were monitored and the expression of RAS components and markers of kidney injury were assessed.
Results
HFD-fed mice exhibited hyperglycemia, insulin resistance, and dyslipidemia compared to those in the RD group (P<0.05). Kidney injury in these mice was indicated by an increase in the ratio of albumin to creatinine, glomerular hypertrophy, and the effacement of podocyte foot processes. Expression of intrarenal angiotensin-converting enzyme, angiotensin II type I receptor, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-4, and monocyte chemoattractant protein-1 was also markedly increased in HFD-fed mice. HFD-fed mice exhibited elevated SBP that was accompanied by an increase in the wall thickness and vascular cross-sectional area (P<0.05), 12 weeks post-HFD consumption. Treatment with THU (100 mg/kg/day) suppressed intrarenal RAS activation, improved insulin sensitivity, and reduced SBP, thus, attenuating kidney injury in these mice.
Conclusion
THU alleviated kidney injury in mice with HFD-induced type 2 diabetes, possibly by blunting the activation of the intrarenal RAS/nicotinamide adenine dinucleotide phosphate oxidase IV (NOX4)/monocyte chemoattractant protein 1 (MCP-1) axis and by lowering the high SBP.

Citations

Citations to this article as recorded by

Synthetic curcumin analogs in nephrotoxicity: Mechanisms and therapeutic advances
Farzaneh Hayati, Sahar Ghoflchi, Asie Sadeghi, Prashant Kesharwani, Amirhossein Sahebkar, Hossein Hosseini
Food and Chemical Toxicology.2026; 209: 115921. CrossRef
NOX4-mediated oxidative stress in diabetic complications: Potential of natural products
Sachin Sharma, Ashwani Mittal, Manjusha Choudhary
Pharmacological Research - Natural Products.2026; 10: 100515. CrossRef
Potential Protective Effects of Curcumin on Aspirin-Induced Toxicity Kidney in Rats
Batrisyia Balqis Mohd Asri, Elysha Nur Ismail, Reezal Ishak
Malaysian Journal of Medicine and Health Sciences.2026; : 1. CrossRef
Tetrahydrocurcumin alleviates di-(2-ethylhexyl) phthalate-induced adipose tissue dysfunction and testicular toxicity in adult mice: possible involvement of adiponectin-adipoR signaling in the testis
Choirul Anwar, Yu-Chi Chu, Mei-Ling Tsai, Chi-Tang Ho, Ching-Shu Lai
Food & Function.2025; 16(2): 583. CrossRef
Repurposing Nano Curcumin: Unveiling its Therapeutic Potential in Diabetic Nephropathy
Rarchita Sharma, Yogesh Mali, Yogeeta. O. Agrawal, Vinit V. Agnihotri, Sameer N. Goyal
Current Drug Targets.2025; 26(5): 298. CrossRef
Research Progress on the Antioxidant Activity of Natural Diarylheptanoids: Mechanisms and Structure–activity Relationships
An-Na Ma, Tie Yao, Ya-Jing Guo, Chong-Yan Zhao, Bing-jie Wang, Gen Li, Feng Qiu
Current Medicinal Chemistry.2025; 32(13): 2494. CrossRef
Research and advances in mouse models of diabetic nephropathy: a narrative review
Kang Xie, Yan Ma, Jingjing Din, Yujie Jin, Siwen Zhang, Shiqiang Liu, Cui Yu, Xu Wu, Chunyan Xing, Lizhuo Wang, Jialin Gao
BMC Nephrology.2025;[Epub] CrossRef
Topical Application of miR-200b-3p by Poloxamer 407-Based Hydrogel Accelerates Diabetic Wound Healing
Wan-Yu Lo, Cian-Huei Sin, Huang-Joe Wang
Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 3845. CrossRef
Combination of THU/ALK-5i exhibits profound anti-MASH activity through suppression of lipogenesis and fibrogenesis
Kampeebhorn Boonloh, Eun Soo Lee, Su Ho Jo, Na Won Park, So Bin Lee, Choon Hee Chung
Scientific Reports.2025;[Epub] CrossRef
The role of tetrahydrocurcumin in disease prevention and treatment
Mengting Zhou, Rui Li, Hua Hua, Ying Dai, Zhujun Yin, Li Li, Jin Zeng, Mengni Yang, Junning Zhao, Ruirong Tan
Food & Function.2024; 15(13): 6798. CrossRef
The Development of Dyslipidemia in Chronic Kidney Disease and Associated Cardiovascular Damage, and the Protective Effects of Curcuminoids
Zeltzin Alejandra Ceja-Galicia, Ana Karina Aranda-Rivera, Isabel Amador-Martínez, Omar Emiliano Aparicio-Trejo, Edilia Tapia, Joyce Trujillo, Victoria Ramírez, José Pedraza-Chaverri
Foods.2023; 12(5): 921. CrossRef
Translation Animal Models of Diabetic Kidney Disease: Biochemical and Histological Phenotypes, Advantages and Limitations
Wenting Luo, Shiyun Tang, Xiang Xiao, Simin Luo, Zixuan Yang, Wei Huang, Songqi Tang
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 1297. CrossRef
Curcumin ameliorates focal segmental glomerulosclerosis by inhibiting apoptosis and oxidative stress in podocytes
Hui Zhang, Qing-Qing Dong, Hua-Pan Shu, Yu-Chi Tu, Qian-Qian Liao, Li-Jun Yao
Archives of Biochemistry and Biophysics.2023; 746: 109728. CrossRef
An examination of the protective effects and molecular mechanisms of curcumin, a polyphenol curcuminoid in diabetic nephropathy
Xiaoyu Zhu, Xingli Xu, Chigang Du, Yanping Su, Lixue Yin, Xiaoqiu Tan, Hui Liu, Yiru Wang, Lei Xu, Xinghua Xu
Biomedicine & Pharmacotherapy.2022; 153: 113438. CrossRef
An integrated bioinformatics analysis and experimental study identified key biomarkers CD300A or CXCL1, pathways and immune infiltration in diabetic nephropathy mice
WEI LIANG, QIANG LUO, ZONGWEI ZHANG, KEJU YANG, ANKANG YANG, QINGJIA CHI, HUAN HU
BIOCELL.2022; 46(8): 1989. CrossRef

Review Article

Diabetes, Obesity and Metabolism
Cardiorenal Protection in Diabetic Kidney Disease: Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, Ayodele Odutayo, David Z.I. Cherney; Endocrinol Metab. 2021;36(2):256-269. Published online April 19, 2021; DOI: https://doi.org/10.3803/EnM.2021.987

13,220 View
342 Download
16 Web of Science
19 Crossref

Abstract PDF PubReader ePub

Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic control, but more recent studies have now shown that their benefits extend to cardiovascular and kidney outcomes. The recent addition of data on the novel mineralocorticoid receptor antagonist (MRA) gives us another approach to further decrease the residual risk of diabetic kidney disease progression. In this review we describe the mechanism of action, key studies, and possible adverse effects related to these three classes of medications. The management of type 2 diabetes now includes an increasing number of medications for the management of comorbidities in a patient population at significant risk of cardiovascular disease and progression of chronic kidney disease. It is from this perspective that we seek to outline the rationale for the sequential and/or combined use of SGLT2 inhibitors, GLP-1 RA and MRAs in patients with type 2 diabetes for heart and kidney protection.

Citations

Citations to this article as recorded by

Construction, evaluation, and applications of renal barrier-on-a-chip system
Tuya Naren, Weikang Lv, Abdellah Aazmi, Yujun Wang, Haoran Yu, Jie Ying Lee, Huixiang Yang, Mengfei Yu, Xiuxiu Jiang, Huayong Yang, Liang Ma
Bioactive Materials.2026; 59: 421. CrossRef
Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
Diabetes, Obesity and Metabolism.2026; 28(3): 1764. CrossRef
Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial
Ayodele Odutayo, Deepak L. Bhatt, Vikas S. Sridhar, Michael Szarek, Christopher P. Cannon, Lawrence A. Leiter, Darren K. McGuire, Julia B. Lewis, Renato D. Lopes, Benjamin M. Scirica, Kausik K. Ray, Michael J. Davies, Phillip Banks, Manon Girard, Subodh V
Circulation: Heart Failure.2026;[Epub] CrossRef
Effects of proANP31–67 in a preclinical model of uninephrectomy and cardiac ischemia/reperfusion injury: cardiac remodeling and tissue biochemical profiling
Gustavo Jose Justo Silva, Sara Stefani, Reza Parvan, Michael Frisk, Xin Shen, Martina Alunni Cardinali, Mari E. Strand, Karoline Bjarnesdatter Rypdal, Mathis Korseberg Stokke, Håvard Attramadal, Ida G. Lunde, Jan Magnus Aronsen, Kåre-Olav Stensløkken, Wil
American Journal of Physiology-Cell Physiology.2026; 330(5): C1246. CrossRef
Combination treatment for the management of chronic kidney disease and type 2 diabetes: a review and practical guidance
Mai Mohsen, Tae Won Yi, Labib Faruque, Calvin Ke, Joseph A Cafazzo, Quynh Pham, Vikas S Sridhar, Adeera Levin, Husam Abdel-Qadir, Frederik Persson, Christoph Wanner, Peter Jüni, Javed Butler, Nikolaus Marx, David Z I Cherney, Ayodele Odutayo
The Journal of Clinical Endocrinology & Metabolism.2026; 111(7): e1726. CrossRef
Personalizing Cardio-Kidney-Metabolic Therapy
Qandeel H. Soomro, David M. Charytan
Journal of the American Society of Nephrology.2026; 37(8): 1619. CrossRef
The Role of GLP-1 Receptor Agonists in Diabetic Kidney Disease: Recent Evidence
Jin Hwa Kim
The Journal of Korean Diabetes.2025; 26(1): 5. CrossRef
Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus
Soumitra Ray, J Ezhilan, Rajiv Karnik, Ashish Prasad, Rajashree Dhar
Journal of Diabetology.2024; 15(2): 131. CrossRef
The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials
Mustafa Arici, Bulent Altun, Mustafa Araz, Aysegul Atmaca, Tevfik Demir, Tevfik Ecder, Galip Guz, Dilek Gogas Yavuz, Alaattin Yildiz, Temel Yilmaz
Frontiers in Medicine.2024;[Epub] CrossRef
Relative and Absolute Risks of Adverse Events with Real-World Use of SGLT2 Inhibitors in CKD
Ayodele Odutayo, Adeera Levin
Clinical Journal of the American Society of Nephrology.2023; 18(5): 557. CrossRef
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim
Endocrinology and Metabolism.2023; 38(1): 43. CrossRef
Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
Eun Sil Koh, Gheun-Ho Kim, Sungjin Chung
Endocrinology and Metabolism.2023; 38(4): 359. CrossRef
SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model
A Young Sim, Da Hyun Choi, Jong Youl Kim, Eun Ran Kim, A-ra Goh, Yong-ho Lee, Jong Eun Lee
Biomedicine & Pharmacotherapy.2023; 168: 115755. CrossRef
Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease
Emma S. Speedtsberg, Martin Tepel
Frontiers in Endocrinology.2023;[Epub] CrossRef
Management of CKD
Nimrit Goraya, Jennifer D. Moran
Nephrology Self-Assessment Program.2022; 21(2): 146. CrossRef
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
Peter Kolkhof, Amer Joseph, Ulrich Kintscher
Pharmacological Research.2021; 172: 105859. CrossRef
Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression
Ayodele Odutayo, Bruno R. da Costa, Tiago V. Pereira, Vinay Garg, Samir Iskander, Fatimah Roble, Rahim Lalji, Cesar A. Hincapié, Aquila Akingbade, Myanca Rodrigues, Arnav Agarwal, Bishoy Lawendy, Pakeezah Saadat, Jacob A. Udell, Francesco Cosentino, Peter
Journal of the American Heart Association.2021;[Epub] CrossRef
Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
Luis D’Marco, María Jesús Puchades, Lorena Gandía, Claudia Forquet, Elena Giménez-Civera, Nayara Panizo, Javier Reque, Isabel Juan-García, Valmore Bermúdez, José Luis Gorriz
touchREVIEWS in Endocrinology.2021; 17(2): 84. CrossRef
Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
Jorge I. Fonseca-Correa, Ricardo Correa-Rotter
Frontiers in Medicine.2021;[Epub] CrossRef

Original Articles

Clinical Study
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis: Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim; Endocrinol Metab. 2021;36(2):388-400. Published online March 31, 2021; DOI: https://doi.org/10.3803/EnM.2020.912

14,273 View
432 Download
18 Web of Science
22 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
To compare the renal effects of dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors on individual outcomes in patients with type 2 diabetes.
Methods
We searched electronic databases (MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials) from inception to June 2019 to identity eligible randomized controlled trials of DPP-4 inhibitors or SGLT2 inhibitors that reported at least one kidney outcome in patients with type 2 diabetes. Outcomes of interest were microalbuminuria, macroalbuminuria, worsening nephropathy, and end-stage kidney disease (ESKD). We performed an arm-based network meta-analysis using Bayesian methods and calculated absolute risks and rank probabilities of each treatment for the outcomes.
Results
Seventeen studies with 87,263 patients were included. SGLT2 inhibitors significantly lowered the risks of individual kidney outcomes, including microalbuminuria (odds ratio [OR], 0.64; 95% credible interval [CrI], 0.41 to 0.93), macroalbuminuria (OR, 0.48; 95% CrI, 0.24 to 0.72), worsening nephropathy (OR, 0.65; 95% CrI, 0.44 to 0.91), and ESKD (OR, 0.65; 95% CrI, 0.46 to 0.98) as compared with placebo. However, DPP-4 inhibitors did not lower the risks. SGLT2 inhibitors were considerably associated with higher absolute risk reductions in all kidney outcomes than DPP-4 inhibitors, although the benefits were statistically insignificant. The rank probabilities showed that SGLT2 inhibitors were better treatments for lowering the risk of albuminuria and ESKD than placebo or DPP-4 inhibitors.
Conclusion
SGLT2 inhibitors were superior to DPP-4 inhibitors in reducing the risk of albuminuria and ESKD in patients with type 2 diabetes.

Citations

Citations to this article as recorded by

Evolving strategies for nephroprotection in diabetic kidney disease: From established therapies to novel interventions
Guido Gembillo, Luca Visconti, Valeria Tranchida, Chiara Nardi, Sebastiano Calimeri, Maria Elsa Gambuzza, Maria Princiotto, Chiara Chinigo, Luca Soraci, Domenico Santoro
World Journal of Diabetes.2026;[Epub] CrossRef
Omarigliptin ameliorates cisplatin-induced renal damage: Cross-talk between glucagon-like peptide-1, HMGB1/RAGE/TLR4 signaling, and TXNIP/NLRP3 inflammasome/gasdermin D axis
Shuruq E. Alsufyani, Hany H. Arab, Azza A.K. El-Sheikh, El-Shaimaa A. Arafa, Ahmed Fouad Hussein Hashad, Reham M. Goda, Tamer M. Naguib, Maaly A. Abd Elmaaboud, Mennatallah A. Elkady, Ahmed M. Kabel
Life Sciences.2025; 376: 123758. CrossRef
Expert consensus on solutions to improve implementation of NICE type 2 diabetes guideline (NG28) by health systems in England: a Delphi panel by the INNOVATE-28 Working Group
Waqas Tahir, Hannah Beba, Gail Fortes-Mayer, Partha Kar, Nazish Khan, Nicola Milne, Jim Moore, Sharvanu Saha, Marc Atkin
BMJ Open.2025; 15(6): e093955. CrossRef
Association between sodium‐glucose cotransporter 2 inhibitor use and clinical outcomes in patients with type 2 diabetes after urinary tract infection
Hsiao‐Wei Wang, Ming‐Hsien Tsai, Yu‐Wei Fang, Kuo‐Cheng Lu, Joshua Wang, Chien‐Lin Lu
Diabetes, Obesity and Metabolism.2025; 27(11): 6188. CrossRef
Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes
Patrizia Natale, Suetonia C Green, David J Tunnicliffe, Giovanni Pellegrino, Tadashi Toyama, Giovanni FM Strippoli
Cochrane Database of Systematic Reviews.2025;[Epub] CrossRef
Therapie des Typ-2-Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Die Diabetologie.2024; 20(2): 212. CrossRef
Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study
Mototsugu Nagao, Jun Sasaki, Kyoko Tanimura-Inagaki, Ichiro Sakuma, Hitoshi Sugihara, Shinichi Oikawa
Cardiovascular Diabetology.2024;[Epub] CrossRef
Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis
Ji Soo Kim, Gyeongsil Lee, Kyung-Il Park, Seung-Won Oh
Diabetes & Metabolism Journal.2024; 48(2): 312. CrossRef
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Experimental and Clinical Endocrinology & Diabetes.2024; 132(07): 340. CrossRef
Clinical Management of Type II DM in patients Showing Progressive Increase in the Creatinine Level – A Cross-sectional Study
Prabhudatta Mohapatra, Durga Madhab Kar, Karmajeet Rath, Abhisek Pal
Research Journal of Pharmacy and Technology.2024; : 2719. CrossRef
Therapie des Typ-2-Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Die Diabetologie.2023; 19(5): 658. CrossRef
Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study
Apichaya Chanawong, Suriyon Uitrakul, Supatcha Incomenoy, Natnicha Poonchuay, Rizky Abdulah
Advances in Pharmacological and Pharmaceutical Sciences.2023; 2023: 1. CrossRef
Different nursing interventions on sleep quality among critically ill patients: A systematic review and network meta-analysis
Daijin Huang, Yumei Li, Jing Ye, Chang Liu, Dongyan Shen, Yunhui Lv
Medicine.2023; 102(52): e36298. CrossRef
New trends in the approach to the treatment of type 2 diabetes - observations and benefits in the outpatient practice of a diabetologist
Pavel Weber, Hana Meluzínová, Dana Weberová
Klinická farmakologie a farmacie.2022; 35(4): 118. CrossRef
Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta‐analysis
Hongwei Cao, Tao Liu, Li Wang, Qiuhe Ji
Diabetes, Obesity and Metabolism.2022; 24(8): 1448. CrossRef
Therapie des Typ-2-Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Die Diabetologie.2022; 18(5): 623. CrossRef
Significant reduction in chronic kidney disease progression with sodium‐glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on inte
Iskandar Idris, Ruiqi Zhang, Jil B. Mamza, Mike Ford, Tamsin Morris, Amitava Banerjee, Kamlesh Khunti
Diabetes, Obesity and Metabolism.2022; 24(11): 2138. CrossRef
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Experimental and Clinical Endocrinology & Diabetes.2022; 130(S 01): S80. CrossRef
Molecular Mechanistic Pathways Targeted by Natural Compounds in the Prevention and Treatment of Diabetic Kidney Disease
Kaixuan Zhou, Xue Zi, Jiayu Song, Qiulu Zhao, Jia Liu, Huiwei Bao, Lijing Li
Molecules.2022; 27(19): 6221. CrossRef
Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
Jiandong Zhou, Xuejin Liu, Oscar Hou-In Chou, Lifang Li, Sharen Lee, Wing Tak Wong, Qingpeng Zhang, Carlin Chang, Tong Liu, Gary Tse, Fengshi Jing, Bernard Man Yung Cheung
Rheumatology.2022;[Epub] CrossRef
New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors
Chan-Hee Jung
Endocrinology and Metabolism.2021; 36(2): 339. CrossRef
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
André J. Scheen
Diabetes & Metabolism.2021; 47(6): 101275. CrossRef

Clinical Study
Association of Vitamin D Deficiency with Diabetic Nephropathy: So-hyeon Hong, Young Bin Kim, Hoon Sung Choi, Tae-Dong Jeong, Jin Taek Kim, Yeon Ah Sung; Endocrinol Metab. 2021;36(1):106-113. Published online February 24, 2021; DOI: https://doi.org/10.3803/EnM.2020.826

14,603 View
279 Download
43 Web of Science
50 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Low 25-hydroxyvitamin D (25OHD) levels are associated with the incidence of type 2 diabetes mellitus (T2DM). However, the association between 25OHD and metabolic health status or diabetic complications is inconclusive. We evaluated this relationship between vitamin D status and metabolic parameters and complications of T2DM.
Methods
This study included 1,392 patients with T2DM who visited Eulji and Ewha Diabetes Center between January 2011 and August 2016. Anthropometric parameters and laboratory tests including glycated hemoglobin (HbA1c), lipid profile, liver and kidney function, and urinary albumin-to-creatinine ratio (UACR) were evaluated. Diabetic macro- and microvascular complications were determined through a medical record review. Serum 25OHD concentrations were measured by chemiluminescent immunoassay.
Results
The mean 25OHD level was 16.8±9.6 ng/mL. Vitamin D deficiency (<20 ng/mL) and severe deficiency (<10 ng/mL) were observed in 990 (71.1%) and 351 (25.2%) participants, respectively. 25OHD level was positively correlated with age and highdensity lipoprotein cholesterol (HDL-C) level and negatively correlated with HbA1c, triglyceride level, and UACR. HDL-C and UACR were significantly associated with 25OHD after adjusting for other variables. Vitamin D deficiency was independently related to nephropathy after adjusting for confounding variables.
Conclusion
Vitamin D deficiency was common among Korean T2DM patients; it was independently associated with microalbuminuria and HDL level, and positively related to diabetic nephropathy.

Citations

Citations to this article as recorded by

Impact of Vitamin D deficiency and VDR FokI polymorphism on diabetic nephropathy risk in type 2 diabetes
Addisu Melake, Misganaw Asmamaw Mengstie
Journal of the National Medical Association.2026; 118(1): 83. CrossRef
Association between triglyceride-glucose index and diabetic kidney disease in adults with type 1 diabetes
Jie Xiang, Wei Gao, Yao Yao, Chan Lu
BMC Endocrine Disorders.2026;[Epub] CrossRef
Prevalence of Hypovitaminosis D Among Patients With Type 2 Diabetes Mellitus: Evidence From a Diabetes Clinic in Durgapur, West Bengal
Sutanuka Saha, Piush Pandey, Indradeep Ganguly, Rakesh Kumar, Soumit Roy, Raghunath Misra, Sayanti Bandyopadhyay, Ankita Banerjee, Anirban Mondal, Subarna Sinha Mahapatra
Cureus.2026;[Epub] CrossRef
Association of 25(OH)D status with calcium metabolism, inflammation, and thyroid autoimmunity in patients with type 2 diabetes mellitus
Nannan Lv, Jianjian Xiang, Jinsong Kuang, Fei Liu, Lan Cheng, Shanyu Yin
Frontiers in Endocrinology.2026;[Epub] CrossRef
Endolymphatic hydrops and its association with Magnetic Resonance Imaging and serum vitamin D levels
Tao Lin, Xiaoting Wang, Luguang Zhang, Jing Li, Ling Ding
Brazilian Journal of Otorhinolaryngology.2026; 92(5): 101858. CrossRef
Vitamin D deficiency and metabolic disorders increase albuminuria risk in type 2 diabetes (ACR 0.1–300 mg/g): a nomogram-based stratification
Yanmei Lin, Chenru Zhao, Kang Du, Jianqing Tian
Frontiers in Endocrinology.2026;[Epub] CrossRef
Construction and validation of a risk prediction model for vitamin D deficiency in patients with type 2 diabetes mellitus
Ying Zhao, Jieru Chen, Fan Feng, Lixing Yang, Peng Zhang, Xia Cui
Frontiers in Nutrition.2026;[Epub] CrossRef
Association of vitamin D deficiency and chronic kidney disease in comorbid patients with type 2 diabetes mellitus
V. A. Dugusheva, Yu. A. Kotova
Meditsinskiy sovet = Medical Council.2026;[Epub] CrossRef
Pathophysiological mechanisms, potential biomarkers, and therapeutic interventions in diabetic nephropathy
Kuldip Vyas, Abu Sufiyan Chhipa, Ayush chauhan, Snehal S. Patel
Discover Molecules.2026;[Epub] CrossRef
Role of vitamin D3 in lipid metabolism and chronic pain in advanced diabetic kidney disease and its rehabilitation
Ning-Ning Zhuang, Hao-Jun You
Healthcare and Rehabilitation.2025; 1(1): 100005. CrossRef
Role of platelet indices and vitamin D in forecasting deterioration of glycemic control and vascular complications in type 2 diabetes
Maryam Ahmed Obaid Al Ali, Khalid Abdelsamea Mohamedahmed, Asaad Ma Babker
Italian Journal of Medicine.2025;[Epub] CrossRef
Vitamin D Status and Its Association With Sun Exposure in Patients With Type 2 Diabetes Mellitus in Southern Malaysia
Norizzati Amsah, Zaleha Md Isa, Norfazilah Ahmad, Zaid Kassim, Siti Nor Athirah Mohamad
Cureus.2025;[Epub] CrossRef
Impact of dioxins and polychlorinated biphenyls on kidney parameters: The modulatory role of vitamin D
Dongdong Zhang, Xixi Qiao, Juan Peng, Jingjing Quan, Zhijun Huang, Bin Yi
Ecotoxicology and Environmental Safety.2025; 294: 118062. CrossRef
Vitamin D deficiency and VDR TaqI polymorphism on diabetic nephropathy risk among type 2 diabetes patients
Addisu Melake, Misganaw Asmamaw Mengstie
Frontiers in Endocrinology.2025;[Epub] CrossRef
Role of vitamin D in the development and progression of diabetic kidney disease: an overview of meta-analyses
Ashna Chackochan, Muhammed Rashid, Swetha R. Reghunath, Pooja Gopal Poojari, Girish Thunga, Shivashankara Kaniyoor Nagri, Vasudeva Guddattu, Revathi P. Shenoy, Vishnu Prasad Shenoy, Leelavathi D. Acharya
Therapeutic Advances in Endocrinology and Metabolism.2025;[Epub] CrossRef
Association Between Vitamin D Receptor Gene Polymorphism and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus
Nardin S. Soliman, Dina Adam El-Shahat, Hala Mohammed Nagy, Gihan Farouk Attia, Amal Abd Elmoniem Selim
Indian Journal of Clinical Biochemistry.2025;[Epub] CrossRef
25-(OH)D Deficiency and the Risk of Minor Amputation in Patients with Diabetes Foot Ulcers: A Chinese Cohort Study
Zhikai Qian, Yongyang Sun, Jinyu Bai, Bo Jiang, Jiaju Zhao
International Journal of General Medicine.2025; Volume 18: 3837. CrossRef
Associations between serum JAML, nesfatin-1, and 25(OH)D and the risk of diabetic kidney disease in patients with type 2 diabetes
Qizhuo Hou, Kangkang Huang, Yunlai Liang, Wenze Yu, Lu Long, Kun Wang, Bin Yi
Scientific Reports.2025;[Epub] CrossRef
Vitamin D Deficiency Is Associated with an Increased Risk of Macroalbuminuria in Chinese Patients with Type 2 Diabetes
Xiulin WANG, Wenjin XIAO
Journal of Nutritional Science and Vitaminology.2025; 71(4): 283. CrossRef
Association of Vitamin D Deficiency with Diabetic Nephropathy in Type 2 Diabetes: A Hospital-Based Cross-Sectional Study
Shafia Bashir, Geer Mohammad Ishaq, Insha Mushtaq, Mohammad Ashraf Ganie, Imtiyaz Wani, Muteb Alanazi, Ibrahim Asiri, Arshad Hussain, Kashif Ullah Khan, Sirajudheen Anwar
Diseases.2025; 13(12): 405. CrossRef
Association Between Vitamin D and Diabetic Kidney Disease
Feride Pınar Altay, Özlem Turhan İyidir, Sevim Güllü
Journal of Clinical Medicine.2025; 15(1): 153. CrossRef
Evaluation the Levels of Pentosidine and Vitamin D3 in Diabetic Nephropathy
Maryam Hiyder Kadum, Khawla A. Shemran, Yasameen AL Saffar
Medical Journal of Babylon.2025; 22(4): 995. CrossRef
Deficiency of 25-Hydroxy Vitamin D in Type 2 Diabetic Patients in Parakou in 2023: Prevalence and Associated Factors
Moutawakilou Gomina, Adébayo Alassani, Diane Naissem Guidimbaye, Sékossounon Sanni, Romaric Basson, Jean-Baptiste Aidjinou, Lassane Zoungrana, Abdou-Badiou Djibril, Jules Gninkoun
Open Journal of Endocrine and Metabolic Diseases.2025; 15(10): 217. CrossRef
ED-71 ameliorates bone regeneration in type 2 diabetes by reducing ferroptosis in osteoblasts via the HIF1α pathway
Maoshan Wang, Yingxue Liu, Houda Gui, Gaoqiang Ma, Binyang Li, Zhanwei Zhang, Gyeonghwi Yu, Ailin Wu, Xin Xu, Dongjiao Zhang
European Journal of Pharmacology.2024; 969: 176303. CrossRef
Vitamin D metabolism in diabetic nephropathy
Z. V. Abilov, R. Kh. Salimkhanov, A. A. Povaliaeva, A. Yu. Zhukov, E. A. Pigarova, L. K. Dzeranova, L. Ya. Rozhinskaya
Obesity and metabolism.2024; 20(4): 283. CrossRef
Telmisartan ameliorates nephropathy and restores the hippo pathway in rats with metabolic syndrome
Badria Mohamed, Salah A. Ghareib, Amira Ebrahim Alsemeh, Shaimaa S. El-Sayed
European Journal of Pharmacology.2024; 973: 176605. CrossRef
The impact of vitamin D on the etiopathogenesis and the progression of type 1 and type 2 diabetes in children and adults
Candong Li, Jiaowen Fu, Yipeng Ye, Junsen Li, Yangli He, Tuanyu Fang
Frontiers in Endocrinology.2024;[Epub] CrossRef
25(OH)D level and vascular lesion scores in kidney histopathology as risk-stratification tool for predicting renal progression in people with type 2 diabetes
Suyan Duan, Fang Lu, Rui Sun, Chen Chen, Si Chen, Luhan Geng, Li Qian, Ying Pan, Chengning Zhang, Ming Zeng, Bin Sun, Huijuan Mao, Bo Zhang, Changying Xing, Yanggang Yuan
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(5): 103037. CrossRef
Relationship between bone turnover markers and renal disease in elderly patients with type 2 diabetes: a cross-sectional study
Shuwu Wei, Xinyu Pan, Junping Wei
BMC Endocrine Disorders.2024;[Epub] CrossRef
COVID-19 infection and metabolic comorbidities: Mitigating role of nutritional sufficiency and drug – nutraceutical combinations of vitamin D
Sumit Kumar Mandal, Meghana Tare, P.R. Deepa
Human Nutrition & Metabolism.2023; 31: 200179. CrossRef
Effects of Vitamin D Supplementation in Diabetic Kidney Disease: A Systematic Review
Thais de Oliveira e Silva Ullmann, Beatrys Juliani Ramalho, Lucas Fornari Laurindo, Ricardo José Tofano, Claudio José Rubira, Elen Landgraf Guiguer, Sandra Maria Barbalho, Uri Adrian Prync Flato, Katia Portero Sloan, Adriano Cressoni Araujo
Journal of Renal Nutrition.2023; 33(5): 618. CrossRef
Diabetic Nephropathy: Significance of Determining Oxidative Stress and Opportunities for Antioxidant Therapies
Marina Darenskaya, Sergey Kolesnikov, Natalya Semenova, Lyubov Kolesnikova
International Journal of Molecular Sciences.2023; 24(15): 12378. CrossRef
Association between serum 25- hydroxyvitamin D and albuminuiria in middle-aged and older Chinese patients with type 2 diabetes
Luyan Zhang, Qian Guo, Yanjia Xu, Wenzhen Wei, Yu Wang
BMC Endocrine Disorders.2023;[Epub] CrossRef
Vitamin D deficiency and its associated factors among patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Mitku Mammo Taderegew, Gashaw Garedew Woldeamanuel, Alemayehu Wondie, Atsede Getawey, Abera Nesiru Abegaz, Fentahun Adane
BMJ Open.2023; 13(10): e075607. CrossRef
Progression of diabetic nephropathy and vitamin D serum levels: A pooled analysis of 7722 patients
Yomna E. Dean, Sameh Samir Elawady, Wangpan Shi, Ahmed A. Salem, Arinnan Chotwatanapong, Haya Ashraf, Tharun Reddi, Prashant Obed Reddy Dundi, Waleed Yasser Habash, Mohamed Yasser Habash, Safaa Ahmed, Hana M. Samir, Ahmed Elsayed, Aryan Arora, Abhinav Aro
Endocrinology, Diabetes & Metabolism.2023;[Epub] CrossRef
Incidence of Vitamin D Deficiency and Its Association With Microalbuminuria in Patients With Type 2 Diabetes Mellitus
Muhammad Hamza Riaz, Ammar Jamil, Hira Yousaf, Muhammad Hassan, Muhammad Ahmer Sohaib, Sharjeel Babar, Muhammad Hassan Ahmad, Ibtesam Allahi, Muhammad Zeshan Mehmood, Tayyab Mumtaz Khan
Cureus.2023;[Epub] CrossRef
The Role of Vitamin D in Diabetic Nephropathy: A Translational Approach
Charlotte Delrue, Reinhart Speeckaert, Joris R. Delanghe, Marijn M. Speeckaert
International Journal of Molecular Sciences.2022; 23(2): 807. CrossRef
Associations of serum amyloid A and 25‐hydroxyvitamin D with diabetic nephropathy: A cross‐sectional study
Qian Liu, Jin Sun, Tongdao Xu, Guangrong Bian, Fumeng Yang
Journal of Clinical Laboratory Analysis.2022;[Epub] CrossRef
Formulation Strategies for Improving the Stability and Bioavailability of Vitamin D-Fortified Beverages: A Review
Elsa F. Vieira, Suene Souza
Foods.2022; 11(6): 847. CrossRef
Association between Vitamin D Status and Mortality among Adults with Diabetic Kidney Disease
Feng Xu, Hongyu Lu, Tianwen Lai, Ling Lin, Yongsong Chen, Pratibha V. Nerurkar
Journal of Diabetes Research.2022; 2022: 1. CrossRef
Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus
Seyed Alireza Zomorodian, Maryam Shafiee, Zeinab Karimi, Fatemeh Masjedi, Amirhossein Roshanshad
BMC Endocrine Disorders.2022;[Epub] CrossRef
Association of Serum 25 (OH) Vitamin D With Chronic Kidney Disease Progression in Type 2 Diabetes
Suyan Duan, Fang Lu, Buyun Wu, Chengning Zhang, Guangyan Nie, Lianqin Sun, Zhimin Huang, Honglei Guo, Bo Zhang, Changying Xing, Yanggang Yuan
Frontiers in Endocrinology.2022;[Epub] CrossRef
The Influence of Dietary Supplementations on Neuropathic Pain
Francesco D’Egidio, Giorgia Lombardozzi, Housem E. Kacem Ben Haj M’Barek, Giada Mastroiacovo, Margherita Alfonsetti, Annamaria Cimini
Life.2022; 12(8): 1125. CrossRef
Emergence of Ectopic Adrenal Tissues-What are the Probable Mechanisms?
Gürkan Tarçın, Oya Ercan
Journal of Clinical Research in Pediatric Endocrinology.2022; 14(3): 258. CrossRef
Anti-proteinuria effect of active vitamin D in patients with type 2 diabetic nephropathy
Asieh Aref, Mina Khodhal, Homeira Rashidi, Zahra Farhangiyan, Saeid Bitaraf
Journal of Family Medicine and Primary Care.2022; 11(12): 7735. CrossRef
Nutritional Supplements for the Treatment of Neuropathic Pain
Khaled M. Abdelrahman, Kevin V. Hackshaw
Biomedicines.2021; 9(6): 674. CrossRef
Vitamin D Deficiency as a Predictor of a High Prevalence of Coronary Artery Disease in Pancreas Transplant Candidates With Type 1 Diabetes
Małgorzata Buksińska-Lisik, Przemysław J. Kwasiborski, Robert Ryczek, Wojciech Lisik, Artur Mamcarz
Frontiers in Endocrinology.2021;[Epub] CrossRef
Serum 25-hydroxyvitamin D and Metabolic Parameters in Healthy Korean Adults: Korean National Health and Nutrition Examination Survey VI
Jeonghoon Ha, Hansang Baek, Chaiho Jeong, Hyunsam Kim, Ki-Hyun Baek, Moo Il Kang, Dong-Jun Lim
International Journal of General Medicine.2021; Volume 14: 5233. CrossRef
Association Between 25(OH)Vitamin D, HbA1c and Albuminuria in Diabetes Mellitus: Data From a Population-Based Study (VIDAMAZON)
João Soares Felício, Hana Andrade de Rider Britto, Pedro Celeira Cortez, Fabrício de Souza Resende, Manuela Nascimento de Lemos, Lorena Vilhena de Moraes, Vitória Teixeira de Aquino, Fernanda de Souza Parente, Natércia Neves Marques de Queiroz, João Felíc
Frontiers in Endocrinology.2021;[Epub] CrossRef
Vitamin D Analogs Can Retard the Onset or Progression of Diabetic Kidney Disease: A Systematic Review
Samuel N. Uwaezuoke
Frontiers in Clinical Diabetes and Healthcare.2021;[Epub] CrossRef

Clinical Study
Short-Term Effects of Beraprost Sodium on the Markers for Cardiovascular Risk Prediction in Type 2 Diabetic Patients with Microalbuminuria: Yun Mi Choi, Hyuk-Sang Kwon, Kyung Mook Choi, Won-Young Lee, Eun-Gyoung Hong; Endocrinol Metab. 2019;34(4):398-405. Published online December 23, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.4.398

10,792 View
69 Download
9 Web of Science
10 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

To evaluate the changes in cardiovascular risk markers including pulse wave velocity (PWV), microalbuminuria, inflammatory cytokines, and adhesion molecules after treatment with beraprost sodium (BPS) in patients with diabetic nephropathy.

Methods

This was a multicenter, prospective, randomized, double-blind, placebo-controlled trial. Type 2 diabetes mellitus patients with microalbuminuria were included. The primary endpoints were changes in microalbuminuria in spot urine and PWV after BPS or placebo (PCB) treatment for 24 weeks. The secondary endpoints were changes in clinical and metabolic parameters.

Results

A total of 52 patients completed the 24-week trial. Changes in PWV were not different significantly in the BPS and PCB groups (right, P=0.16; left, P=0.11). Changes in microalbuminuria were 14.2±157.0 and 34.5±146.6 (µg/mg Cr) in the BPS and PCB groups, respectively (P=0.63). Subgroup analysis in the high blood pressure (BP) group (baseline systolic BP >120 mm Hg and diastolic BP >80 mm Hg), showed that microalbuminuria decreased by −47.6 in the BPS group compared with an increase by 116.4 (µg/mg Cr) in the PCB group (P=0.04). Also, in the large waist circumference group (>95 cm), microalbuminuria decreased significantly in the BPS group (P=0.04).

Conclusion

Short-term treatment of BPS for patients with diabetic nephropathy did not show significant improvement in various cardiovascular risk factors. However, BPS significantly decreased microalbuminuria in study subjects with higher cardiovascular risk such as high BP or large waist circumference.

Citations

Citations to this article as recorded by

A meta-analysis examining the impact of prostaglandins on diabetic nephropathy
Xiafei Guo
International Urology and Nephrology.2025; 57(7): 2301. CrossRef
Development of Predictive Models for Progression from Diabetic Kidney Disease to End-Stage Renal Disease in Type 2 Diabetes Mellitus: A Retrospective Cohort Study
Huiyue Hu, Xiaodie Mu, Shuya Zhao, Min Yang, Hua Zhou
Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 383. CrossRef
Clinical efficacy of beraprost sodium in treating chronic kidney disease: A six-month prospective study
Chen Sun, Xin Wu, Xin Zhang, Shulin Li, Ruoyu Jia, Dong Sun
Heliyon.2024; 10(2): e24156. CrossRef
Clinical efficacy and safety of beraprost sodium in the treatment of nephrotic syndrome: A meta-analysis
Peng Yan, Ben Ke, Xiangdong Fang
Medicine.2023; 102(42): e34958. CrossRef
Dysregulated coagulation system links to inflammation in diabetic kidney disease
Mengyun Xiao, Donge Tang, Shaodong Luan, Bo Hu, Wenyu Gong, Wolfgang Pommer, Yong Dai, Lianghong Yin
Frontiers in Clinical Diabetes and Healthcare.2023;[Epub] CrossRef
Plasma plasminogen activator inhibitor-1 as a predictive marker of type 2 diabetic nephropathy in Egyptian patients
El-Saeid M.E.-S. El-Bawab, Mostafa M.M. Alomairi, Ashraf M. El- Kabeer, Sayed F.A. Abd-Allah
Al-Azhar Assiut Medical Journal.2023; 21(3): 178. CrossRef
The effects of beraprost sodium on renal function and cardiometabolic profile in patients with diabetes mellitus: a systematic review and meta-analysis of clinical trials
Peyman Nowrouzi-Sohrabi, Reza Tabrizi, Kamran Hessami, Mojtaba Shabani-Borujeni, Mahnaz Hosseini-Bensenjan, Shahla Rezaei, Mohammad Jalali, Pedram Keshavarz, Fariba Ahmadizar
International Urology and Nephrology.2022; 54(1): 111. CrossRef
Thrombocytopenia in COVID‑19 and vaccine‑induced thrombotic thrombocytopenia
Styliani Geronikolou, Işil Takan, Athanasia Pavlopoulou, Marina Mantzourani, George Chrousos
International Journal of Molecular Medicine.2022;[Epub] CrossRef
The Role of Platelets in Diabetic Kidney Disease
Ukhti Jamil Rustiasari, Joris J. Roelofs
International Journal of Molecular Sciences.2022; 23(15): 8270. CrossRef
Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes Therapy.2021; 12(1): 171. CrossRef

Diabetes, Obesity and Metabolism
Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis: Jae Hyun Bae, Sunhee Kim, Eun-Gee Park, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim; Endocrinol Metab. 2019;34(1):80-92. Published online March 21, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.1.80

14,785 View
321 Download
47 Web of Science
50 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

To investigate the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal outcomes in patients with type 2 diabetes.

Methods

MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched to identify randomized controlled trials (RCTs) of DPP-4 inhibitors from inception to September 2017. We selected eligible RCTs comparing DPP-4 inhibitors with placebo or other antidiabetic agents and reporting at least one renal outcome. A meta-analysis was conducted to calculate standardized mean differences, weighted mean differences (WMDs), relative risks (RRs), and 95% confidence intervals (CIs) for each renal outcome.

Results

We included 23 RCTs with 19 publications involving 41,359 patients. Overall changes in urine albumin-to-creatinine ratio were comparable between DPP-4 inhibitors and controls (P=0.150). However, DPP-4 inhibitors were associated with significantly lower risk of incident microalbuminuria (RR, 0.89; 95% CI, 0.80 to 0.98; P=0.022) and macroalbuminuria (RR, 0.77; 95% CI, 0.61 to 0.97; P=0.027), as well as higher rates of regression of albuminuria (RR, 1.22; 95% CI, 1.10 to 1.35; P<0.001) compared with controls. Although DPP-4 inhibitors were associated with small but significantly lower estimated glomerular filtration rate (WMD, −1.11 mL/min/1.73 m²; 95% CI, −1.78 to −0.44; P=0.001), there was no difference in the risk of end-stage renal disease between two groups (RR, 0.93; 95% CI, 0.76 to 1.14; P=0.475).

Conclusion

DPP-4 inhibitors had beneficial renal effects mainly by reducing the risk of development or progression of albuminuria compared with placebo or other antidiabetic agents.

Citations

Citations to this article as recorded by

Real-World Evidence for Metformin Use in Solid Organ Transplant Recipients Living With Diabetes
Idit Dotan, Shiri Kushnir, Tzippy Shochat, Talia Diker Cohen
Endocrine Practice.2026; 32(3): 360. CrossRef
Gene Expression as a Guide for the Development of Novel Therapies in Hypertensive and Diabetic Kidney Disease
Maria Zaimi, Georgios Zagkotsis, Athanasios Kammenos, Eirini Grapsa, Smaragdi Marinaki, Eleni Frangou
Journal of Clinical Medicine.2026; 15(2): 696. CrossRef
Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24‐week, randomized, open‐label, multicenter trial
So Ra Kim, Jun Hwa Hong, Sin Gon Kim, Soo‐Kyung Kim, Hyuk‐Sang Kwon, Jun Sung Moon, Jung Hwan Park, Jae Myung Yu, Bong‐Soo Cha, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2026; 28(4): 3305. CrossRef
Early potential safety signals for gliptins and gliflozins using real-world pharmacy data compared to spontaneous reporting
Maria-Isabel Jimenez-Serrania, Sara-Maria Martinez-Gonzalez, Javier Herradon-Muñoz, Carlos Treceño-Lobato, Marwan Salih Al-Nimer
PLOS One.2026; 21(6): e0352399. CrossRef
Positive impact of DPP-4 or SGLT2 inhibitors on mild cognitive impairment in type 2 diabetes patients on metformin therapy: A metabolomic mechanistic insight
Shams T. Osman, Waziha Purba, Oluwatosin Daramola, Md Mostofa Al Amin Bhuiyan, Judith Nwaiwu, Mojibola Fowowe, Junyao Wang, Noha A. Hamdy, Mahmoud A. Agami, Amr Y. El-Feky, Labiba K. El-Khordagui, Yehia S. Mechref, Ahmed F. El-Yazbi
Biomedicine & Pharmacotherapy.2025; 182: 117771. CrossRef
Use of dipeptidyl peptidase‐4 inhibitors is associated with lower risk of severe renal outcomes in pre‐dialysis patients with Type 2 diabetes
Tung‐Ying Hung, Tzu‐Chieh Lin, Ying‐Jay Liou, Tzu‐Han Lin, Yu‐Juei Hsu, Liang‐Yu Lin, Meng‐Ting Wang
Journal of Internal Medicine.2025; 298(3): 214. CrossRef
Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study
Mototsugu Nagao, Jun Sasaki, Kyoko Tanimura-Inagaki, Ichiro Sakuma, Hitoshi Sugihara, Shinichi Oikawa
Cardiovascular Diabetology.2024;[Epub] CrossRef
Repurposing DPP-4 Inhibitors as a Novel Intervention in COVID-19: In Silico Analysis for SARS-CoV-2 Spike Glycoprotein Inhibition
Chhanda Charan Danta, Manoj Kumar Mahapatra
Proceedings of the National Academy of Sciences, India Section B: Biological Sciences.2024; 94(3): 635. CrossRef
Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
Yong Gong, Xueyan Bai, Donglei Zhang, Xingsheng Yang, Zheng Qin, Yu Yang, Yilun Zhou, Jie Meng, Xin Liu
Lipids in Health and Disease.2024;[Epub] CrossRef
Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users
Hideaki Hashimoto, Michihiro Satoh, Shingo Nakayama, Maya Toyama, Takahisa Murakami, Taku Obara, Naoki Nakaya, Takefumi Mori, Atushi Hozawa, Hirohito Metoki
Diabetes, Obesity and Metabolism.2024; 26(10): 4460. CrossRef
Safety and Efficiency of Dipeptidyl Peptidase IV Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Meta-Analysis
Adili Tuersun, Munire Mohetaer, Guanxin Hou, Gang Cheng
Current Therapeutic Research.2024; 101: 100763. CrossRef
Transforming Diabetes Care: The Expanding Role of DPP-4 Inhibitors in Cardiovascular and Renal Protection
Francisco Epelde
Medicina.2024; 60(11): 1793. CrossRef
Dulaglutide and Dapagliflozin Combination Concurrently Improves the Endothelial Glycocalyx and Vascular and Myocardial Function in Patients with T2DM and Albuminuria vs. DPP-4i
Emmanouil Korakas, John Thymis, Evangelos Oikonomou, Konstantinos Mourouzis, Aikaterini Kountouri, Loukia Pliouta, Sotirios Pililis, George Pavlidis, Stamatios Lampsas, Konstantinos Katogiannis, Lina Palaiodimou, Georgios Tsivgoulis, Gerasimos Siasos, Ign
Journal of Clinical Medicine.2024; 13(24): 7497. CrossRef
Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events
Edoardo Mannucci, Marco Gallo, Andrea Giaccari, Riccardo Candido, Basilio Pintaudi, Giovanni Targher, Matteo Monami
Diabetes, Obesity and Metabolism.2023; 25(2): 444. CrossRef
Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway
Sarah M. AL-Qabbaa, Samaher I. Qaboli, Tahani K. Alshammari, Maha A. Alamin, Haya M. Alrajeh, Lama A. Almuthnabi, Rana R. Alotaibi, Asma S. Alonazi, Anfal F. Bin Dayel, Nawal M. Alrasheed, Nouf M. Alrasheed
International Journal of Molecular Sciences.2023; 24(7): 6532. CrossRef
Take an individualized and multipronged approach when managing older adults with type 2 diabetes
Sheridan M. Hoy
Drugs & Therapy Perspectives.2023; 39(5): 171. CrossRef
Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh
Endocrine Practice.2023; 29(7): 509. CrossRef
Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study
Cheuk To Chung, Ishan Lakhani, Oscar Hou In Chou, Teddy Tai Loy Lee, Edward Christopher Dee, Kenrick Ng, Wing Tak Wong, Tong Liu, Sharen Lee, Qingpeng Zhang, Bernard Man Yung Cheung, Gary Tse, Jiandong Zhou
Cancer Medicine.2023; 12(11): 12299. CrossRef
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes
Deborah J. Wexler, Ian H. de Boer, Alokananda Ghosh, Naji Younes, Ionut Bebu, Silvio E. Inzucchi, Janet B. McGill, Sunder Mudaliar, David Schade, Michael W. Steffes, William V. Tamborlane, Meng H. Tan, Faramarz Ismail-Beigi, Jill P. Crandall, Melissa Dian
JAMA Internal Medicine.2023; 183(7): 705. CrossRef
SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
M. Ganeva
Trakia Journal of Sciences.2023; 21(1): 54. CrossRef
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Christian W. Mende
Advances in Therapy.2022; 39(1): 148. CrossRef
Management of Hyperglycemia in Older Adults with Type 2 Diabetes
Gunjan Y. Gandhi, Arshag D. Mooradian
Drugs & Aging.2022; 39(1): 39. CrossRef
Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review
Zhen Ruan, Huimin Zou, Qing Lei, Carolina Oi Lam Ung, Honghao Shi, Hao Hu
Expert Review of Pharmacoeconomics & Outcomes Research.2022; 22(4): 555. CrossRef
Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
Hiroki Teragawa, Takeshi Morimoto, Yuichi Fujii, Tomohiro Ueda, Mio Sakuma, Michio Shimabukuro, Osamu Arasaki, Koichi Node, Takashi Nomiyama, Shinichiro Ueda
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 685. CrossRef
Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs
Hyo Jin Kim, Sang Soo Kim, Sang Heon Song
The Korean Journal of Internal Medicine.2022; 37(3): 502. CrossRef
The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus
Wan-Chia Hsu, Chun-Sheng Lin, Jung-Fu Chen, Chih-Min Chang
Journal of Clinical Medicine.2022; 11(9): 2653. CrossRef
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Hiroaki Yagyu, Hitoshi Shimano
Journal of Diabetes Investigation.2022; 13(9): 1472. CrossRef
Finerenone, a Novel and Safer Approach toward Management of Diabetic Kidney Disease with Heart Failure
Ayesha Abdul Qadir Memon, Sarmad Iqbal
Global Journal of Medical, Pharmaceutical, and Biomedical Update.2022; 17: 12. CrossRef
The effects of dipeptidyl peptidase‐4 inhibitors on kidney outcomes
Daniel V. O'Hara, Thomas R. Parkhill, Sunil V. Badve, Min Jun, Meg J. Jardine, Vlado Perkovic
Diabetes, Obesity and Metabolism.2021; 23(3): 763. CrossRef
Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD
Acaris Benetti, Flavia Letícia Martins, Letícia Barros Sene, Maria Heloisa M. Shimizu, Antonio C. Seguro, Weverton M. Luchi, Adriana C. C. Girardi
American Journal of Physiology-Renal Physiology.2021; 320(3): F285. CrossRef
Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists
Johannes F.E. Mann, Marcel H.A. Muskiet
Kidney International.2021; 99(2): 314. CrossRef
Renoprotective Effects of DPP-4 Inhibitors
Daiji Kawanami, Yuichi Takashi, Hiroyuki Takahashi, Ryoko Motonaga, Makito Tanabe
Antioxidants.2021; 10(2): 246. CrossRef
Danegaptide Prevents TGFβ1-Induced Damage in Human Proximal Tubule Epithelial Cells of the Kidney
Paul E. Squires, Gareth W. Price, Ulrik Mouritzen, Joe A. Potter, Bethany M. Williams, Claire E. Hills
International Journal of Molecular Sciences.2021; 22(6): 2809. CrossRef
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
Endocrinology and Metabolism.2021; 36(2): 388. CrossRef
Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes
Jack Wei Chieh Tan, David Sim, Junya Ako, Wael Almahmeed, Mark E Cooper, Jamshed J Dalal, Chaicharn Deerochanawong, David Wei Chun Huang, Sofian Johar, Upendra Kaul, Sin Gon Kim, Natalie Koh, Alice Pik-Shan Kong, Rungroj Krittayaphong, Bernard Kwok, Bien
European Cardiology Review.2021;[Epub] CrossRef
Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
Francesco Prattichizzo, Paola de Candia, Antonio Ceriello
Metabolism.2021; 120: 154799. CrossRef
SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease
Robert C. Stanton
Seminars in Nephrology.2021; 41(2): 85. CrossRef
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Nina Vodošek Hojs, Sebastjan Bevc, Robert Ekart, Nejc Piko, Tadej Petreski, Radovan Hojs
Pharmaceuticals.2021; 14(6): 561. CrossRef
Podocyte Glucocorticoid Receptors Are Essential for Glomerular Endothelial Cell Homeostasis in Diabetes Mellitus
Swayam Prakash Srivastava, Han Zhou, Ocean Setia, Alan Dardik, Carlos Fernandez‐Hernando, Julie Goodwin
Journal of the American Heart Association.2021;[Epub] CrossRef
Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease
Swayam Prakash Srivastava, Rohit Srivastava, Subhash Chand, Julie E. Goodwin
Pharmaceuticals.2021; 14(8): 751. CrossRef
Effects of DPP4 inhibitors on renal outcomes in diabetes mellitus: A systematic review and meta-analysis
SaikatK Dalui, Raja Chakraverty, Nafisha Yasmin, Smita Pattanaik, Kaushik Pandit, Suparna Chatterjee
Indian Journal of Endocrinology and Metabolism.2021; 25(4): 283. CrossRef
Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
Yueh-Ting Lee, Chien-Ning Hsu, Chung-Ming Fu, Shih-Wei Wang, Chiang-Chi Huang, Lung-Chih Li
Frontiers in Pharmacology.2021;[Epub] CrossRef
The Role of DPP-4 Inhibitors in Type-2 Diabetes Patients with Chronic Kidney Disease
Mishal Yousef Alqurashi, Khalid Faisal Alharthi, Abdulaziz Abdulrahman Alshehri, Yazeed Khalid Alharbi, Mohammad Abdulmunem Sanousi, Anas Abdullah Almazyed, Khulud Saeed Alghamdi, Sarah Musaad Alrashidi, Waad Abdullah Qaeed, Amjad Aedh Alasmari
Pharmacophore.2021; 12(3): 91. CrossRef
Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
Zoi Kleinaki, Stella Kapnisi, Sofia-Andriani Theodorelou-Charitou, Ilias P. Nikas, Stavroula A. Paschou
Hormones.2020; 19(4): 467. CrossRef
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy.2020; 11(2): 369. CrossRef
Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Rong-Nan Chien, Ming-Jui Hung, Yuk-Ying Chan, Yea-Huei Kao Yang, Edward Chia-Cheng Lai
Cardiovascular Diabetology.2020;[Epub] CrossRef
Novel therapeutic agents for the treatment of diabetic kidney disease
Rachel E. Hartman, P.S.S. Rao, Mariann D. Churchwell, Susan J. Lewis
Expert Opinion on Investigational Drugs.2020; 29(11): 1277. CrossRef
Renal protection with glucagon-like peptide-1 receptor agonists
Martina Vitale, Jonida Haxhi, Tiziana Cirrito, Giuseppe Pugliese
Current Opinion in Pharmacology.2020; 54: 91. CrossRef
Loss of Mitochondrial Control Impacts Renal Health
Swayam Prakash Srivastava, Keizo Kanasaki, Julie E. Goodwin
Frontiers in Pharmacology.2020;[Epub] CrossRef
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
Scientific Reports.2019;[Epub] CrossRef

Review Article

Diabetes, Obesity and Metabolism
Current Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve Outcomes: Sang Soo Kim, Jong Ho Kim, In Joo Kim; Endocrinol Metab. 2016;31(2):245-253. Published online May 27, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.2.245

16,323 View
152 Download
57 Web of Science
55 Crossref

Abstract PDF PubReader

Diabetes is often associated with chronic kidney disease (CKD) and is the primary cause of kidney failure in half of patients who receive dialysis therapy. Given the increasing prevalence of diabetes and its high morbidity and mortality, diabetic nephropathy is a serious drawback in individual patients and a tremendous socioeconomic burden on society. Despite growing concern for the management of diabetic nephropathy, the prevalence of CKD with diabetes is the same today as it was 20 years ago. The current strategy to manage diabetic nephropathy, including the control of hyperglycemia, dyslipidemia, and blood pressure and the wide-spread use of renin-angiotensin-aldosterone system inhibitors, is well established to be beneficial in the early stages of diabetic nephropathy. However, the effects are uncertain in patients with relatively progressed CKD. Therefore, early diagnosis or risk verification is extremely important in order to reduce the individual and socioeconomic burdens associated with diabetic nephropathy by providing appropriate management to prevent the development and progression of this condition. This review focuses on recent research and guidelines regarding risk assessment, advances in medical treatment, and challenges of and future treatments for diabetic nephropathy.

Citations

Citations to this article as recorded by

Translational advances in diabetic nephropathy management: integrating nanoformulation-based drug delivery systems
Mohd Danish Ansari, Ashish Vishwakarma, Md Quamuddin, Mansi Aggarwal, Hashim Khan, Muhammad Fauzi Abd Jalil, Syed Mahmood, Adil Farooq Wali, Sirajunisa Talath, Mohamed El-Tanani
Frontiers in Medical Technology.2026;[Epub] CrossRef
Effect of Probiotic Supplementation on Azotemia and Proteinuria in Patients with Diabetic Kidney Disease: A Randomized Controlled Trial
Ni Ni Aung
Myanmar Medical Journal.2026;[Epub] CrossRef
Implementing novel complete blood count-derived inflammatory indices in the diabetic kidney diseases diagnostic models
Ali Hassanzadeh, Mehdi Allahdadi, Sepehr Nayebirad, Nazli Namazi, Ensieh Nasli-Esfahani
Journal of Diabetes & Metabolic Disorders.2025;[Epub] CrossRef
Role of shearing wave elastography in detecting early diabetic nephropathy
Amr M. Shaker, Shaza Y. Sleem, Mayssa I. Aly, Asmaa H. Habib, Mona G. Hassan
Irish Journal of Medical Science (1971 -).2025; 194(2): 529. CrossRef
Initial Evaluation of Patients with Diabetes Mellitus according to Clinical Guidelines
Dughyun Choi
The Journal of Korean Diabetes.2025; 26(2): 69. CrossRef
U-TXM: a novel biomarker for early detection of diabetic kidney disease
Yujie Jin, Jiahao Xu, Yan Ma, Chunchen Ni, Yan Yao, Shujuan Shang, Mengru Wang, Chunyan Xing, Song Dong, Chaoqun Xiong, Kang Xie, Ruixi Zhang, Wenjun Pei, Shiqiang Liu, Jinhan Cheng, Fan Liu, Siwen Zhang, Dong Li, Lizhuo Wang, Liuming Yu, Jialin Gao
Frontiers in Endocrinology.2025;[Epub] CrossRef
The Role of Angiotensin-Converting Enzyme (ACE) Polymorphisms in the Risk of Development and Treatment of Diabetic Nephropathy
Magdalena Król-Kulikowska, Nikita Abramenko, Milan Jakubek, Mirosław Banasik, Marta Kepinska
Journal of Clinical Medicine.2024; 13(4): 995. CrossRef
Diagnostic utility of renal shear wave elastography and renal Doppler findings in diabetic nephropathy: a case–control study
Ahmed Abdelrahman Baz, Eman Muhammad Abdeen, Mona Yousry Helmy, Abo El-Magd Al-Bohy
Egyptian Journal of Radiology and Nuclear Medicine.2024;[Epub] CrossRef
Schisandrin A Attenuates Diabetic Nephropathy via EGFR/AKT/GSK3β Signaling Pathway Based on Network Pharmacology and Experimental Validation
Pengyu Wang, Qing Lan, Qi Huang, Ruyi Zhang, Shuo Zhang, Leiming Yang, Yan Song, Tong Wang, Guandi Ma, Xiufen Liu, Xiying Guo, Youzhi Zhang, Chao Liu
Biology.2024; 13(8): 597. CrossRef
Network Pharmacology and Experimental Analysis to Explore the Effect and Mechanism of Modified Buyang Huanwu Decoction in the Treatment of Diabetic Nephropathy
Fan Yang, Limin Pan, Xiaoyun Zhang, Jiaan Huang, Yan Liu, Peixuan Li, Yuehua Wang
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 3249. CrossRef
Le diabétique en périopératoire
M. Raucoules-Aimé, T.N. Ouattara
EMC - Endocrinologie - Nutrition.2024; 35(4): 1. CrossRef
Gestione perioperatoria del paziente diabetico adulto
M. Raucoules-Aimé, T. Thierry Nessan Ouattara
EMC - Anestesia-Rianimazione.2023; 28(1): 1. CrossRef
Pyruvate Kinase M2: A New Biomarker for the Early Detection of Diabetes-Induced Nephropathy
Yeon Su Park, Joo Hee Han, Jae Hyeon Park, Ji Soo Choi, Seung Hyeon Kim, Hyung Sik Kim
International Journal of Molecular Sciences.2023; 24(3): 2683. CrossRef
Tratamiento perioperatorio del paciente diabético adulto
M. Raucoules-Aimé, T. Thierry Nessan Ouattara
EMC - Anestesia-Reanimación.2023; 49(1): 1. CrossRef
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim
Endocrinology and Metabolism.2023; 38(1): 43. CrossRef
The role of tubulointerstitial markers in differential diagnosis and prognosis in patients with type 2 diabetes and biopsy proven diabetic kidney disease
Xijian Wang, Liang Ren, Ying Huang, Zhengang Feng, Guangdi Zhang, Houyong Dai
Clinica Chimica Acta.2023; 547: 117448. CrossRef
Network pharmacology and molecular docking technology-based predictive study of the active ingredients and potential targets of rhubarb for the treatment of diabetic nephropathy
Shaojie Fu, Yena Zhou, Cong Hu, Zhonggao Xu, Jie Hou
BMC Complementary Medicine and Therapies.2022;[Epub] CrossRef
Acrolein plays a culprit role in the pathogenesis of diabetic nephropathy in vitro and in vivo
Zhen-Jie Tong, Chin-Wei Kuo, Po-Cheng Yen, Chih-Ching Lin, Ming-Tsun Tsai, Shing-Hwa Lu, Yi-Ping Chang, Wen-Sheng Liu, Han-Hsing Tsou, Hsiao-Wei Cheng, Hsiang-Tsui Wang
European Journal of Endocrinology.2022; 187(4): 579. CrossRef
Prise en charge périopératoire du patient diabétique adulte
M. Raucoules-Aimé, T. Thierry Nessan Ouattara
EMC - Anesthésie-Réanimation.2022; 42(4): 1. CrossRef
Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study
Hongyang Jiang, Yan Zhang, Dongyan Xu, Qing Wang
Journal of Clinical Laboratory Analysis.2021;[Epub] CrossRef
Blood Oxygen Level-Dependent (BOLD) MRI in Glomerular Disease
Daniel R. Nemirovsky, Puneet Gupta, Sophia Hu, Raymond Wong, Avnesh S. Thakor
Transplantology.2021; 2(2): 109. CrossRef
Amelioration of STZ-induced nephropathy in diabetic rats by saffron hydro alcoholic extract
Jamal Amri, Mona Alaee, Seyed Amirhossein Latifi, Abbas Alimoradian, Mehdi Salehi
Hormone Molecular Biology and Clinical Investigation.2021; 42(4): 411. CrossRef
Exosomes: Biomarkers and Therapeutic Targets of Diabetic Vascular Complications
Anqi Chen, Hailing Wang, Ying Su, Chunlin Zhang, Yanmei Qiu, Yifan Zhou, Yan Wan, Bo Hu, Yanan Li
Frontiers in Endocrinology.2021;[Epub] CrossRef
Sodium-glucose cotransporter 2 inhibitors benefit to kidney and cardiovascular outcomes for patients with type 2 diabetes mellitus and chronic kidney disease 3b-4: A systematic review and meta-analysis of randomized clinical trials
Haiyan Cao, Youxia Liu, Zhixia Tian, Yuhang Lian, Junya Jia, Ming Liu, Dong Li
Diabetes Research and Clinical Practice.2021; 180: 109033. CrossRef
Proteinuria as a significant predictive factor for the progression of carotid artery atherosclerosis in non-albuminuric type 2 diabetes
Young-eun Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-soo Cha, Byung-Wan Lee
Diabetes Research and Clinical Practice.2021; 181: 109082. CrossRef
The Role of Mesenchymal Stromal Cells-Derived Small Extracellular Vesicles in Diabetes and Its Chronic Complications
Fu-Xing-Zi Li, Xiao Lin, Feng Xu, Su-Kang Shan, Bei Guo, Li-Min Lei, Ming-Hui Zheng, Yi Wang, Qiu-Shuang Xu, Ling-Qing Yuan
Frontiers in Endocrinology.2021;[Epub] CrossRef
Preparation of Ergosterol-Loaded Nanostructured Lipid Carriers for Enhancing Oral Bioavailability and Antidiabetic Nephropathy Effects
Zhonghua Dong, Sajid Iqbal, Zhongxi Zhao
AAPS PharmSciTech.2020;[Epub] CrossRef
Carbon dots as fluorescent nanoprobe for the determination of N-acetyl-β-d-glucosaminidase activity
Jimei Ma, Heng Zhang, Fangfang Peng, Xiaoqing Yang, Zi-Long Li, Linhao Sun, Hong Jiang
Analytica Chimica Acta.2020; 1101: 129. CrossRef
Coffee Consumption is Associated with a Decreased Risk of Incident Chronic Kidney Disease: A Systematic Review and Meta-analysis of Cohort Studies
Thatsaphan Srithongkul, Patompong Ungprasert
European Journal of Internal Medicine.2020; 77: 111. CrossRef
Understanding molecular upsets in diabetic nephropathy to identify novel targets and treatment opportunities
Nidhi Raval, Akshant Kumawat, Dnyaneshwar Kalyane, Kiran Kalia, Rakesh K. Tekade
Drug Discovery Today.2020; 25(5): 862. CrossRef
A meta-analysis of serum Hcy in diagnosis of diabetic nephropathy
Xiaoling Zhou, Aijie Shi, Xiao Zhou
Pteridines.2020; 31(1): 1. CrossRef
Link between ACE I/D gene polymorphism and dyslipidemia in diabetic nephropathy: A case-control study from Hyderabad, India
UmmeNajiya Mahwish, KamakshiChaithri Ponnaluri, Babi Heera, SatishReddy Alavala, KRudrama Devi, SreeBhushan Raju, GSuman Latha, Parveen Jahan
Indian Journal of Nephrology.2020; 30(2): 77. CrossRef
Assessment of urinary NGAL for differential diagnosis and progression of diabetic kidney disease
Suyan Duan, Jiajia Chen, Lin Wu, Guangyan Nie, Lianqin Sun, Chengning Zhang, Zhimin Huang, Changying Xing, Bo Zhang, Yanggang Yuan
Journal of Diabetes and its Complications.2020; 34(10): 107665. CrossRef
Urinary Proteins Detected Using Modern Proteomics Intervene in Early Type 2 Diabetic Kidney Disease – A Pilot Study
Alina Golea-Secara, Cristian Munteanu, Mirela Sarbu, Octavian M Cretu, Silvia Velciov, Adrian Vlad, Flaviu Bob, Florica Gadalean, Cristina Gluhovschi, Oana Milas, Anca Simulescu, Maria Mogos-Stefan, Mihaela Patruica, Ligia Petrica, Alina D Zamfir
Biomarkers in Medicine.2020; 14(16): 1521. CrossRef
Efficacy and safety of Shenkang injection as adjuvant therapy in patients with diabetic nephropathy
Yanping Wang, Mingzhu Li, Chenyun Li, Sheng Xu, Jiangfeng Wu, Gaochuan Zhang, Yuanyuan Cai
Medicine.2020; 99(52): e23821. CrossRef
A Nucleoside/Nucleobase-Rich Extract from Cordyceps Sinensis Inhibits the Epithelial–Mesenchymal Transition and Protects against Renal Fibrosis in Diabetic Nephropathy
Zhonghua Dong, Yueyue Sun, Guangwei Wei, Siying Li, Zhongxi Zhao
Molecules.2019; 24(22): 4119. CrossRef
Lack of Association between Past Helicobacter pylori Infection and Diabetes: A Two-Cohort Study
Jeung Hui Pyo, Hyuk Lee, Sung Chul Choi, Soo Jin Cho, Yoon-Ho Choi, Yang Won Min, Byung-Hoon Min, Jun Haeng Lee, Heejin Yoo, Kyunga Kim, Jae J. Kim
Nutrients.2019; 11(8): 1874. CrossRef
Serum Homocysteine, cystatin C as Biomarkers for Progression of Diabetic Nephropathy
Weihai Xu, Suhua Tang, Meijuan Xiang, Jianyun Peng
Pteridines.2019; 30(1): 183. CrossRef
Serum leptin in diabetic nephropathy male patients from Gaza Strip
Maged M. Yassin, Ayman M. AbuMustafa, Mohamed M. Yassin
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(2): 1245. CrossRef
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
Scientific Reports.2019;[Epub] CrossRef
Association between nonalbumin proteinuria and renal tubular damage of N-acetyl-β-d-glucosaminidase and its clinical relevance in patients with type 2 diabetes without albuminuria
Eugene Han, Mi-Kyung Kim, Yong-ho Lee, Hye Soon Kim, Byung-Wan Lee
Journal of Diabetes and its Complications.2019; 33(3): 255. CrossRef
Supplementation of Abelmoschus manihot Ameliorates Diabetic Nephropathy and Hepatic Steatosis by Activating Autophagy in Mice
Hwajin Kim, Theodomir Dusabimana, So Ra Kim, Jihyun Je, Kyuho Jeong, Min Cheol Kang, Kye Man Cho, Hye Jung Kim, Sang Won Park
Nutrients.2018; 10(11): 1703. CrossRef
Perioperative management of adult diabetic patients. Preoperative period
Gaëlle Cheisson, Sophie Jacqueminet, Emmanuel Cosson, Carole Ichai, Anne-Marie Leguerrier, Bogdan Nicolescu-Catargi, Alexandre Ouattara, Igor Tauveron, Paul Valensi, Dan Benhamou
Anaesthesia Critical Care & Pain Medicine.2018; 37: S9. CrossRef
Practical management of diabetes patients before, during and after surgery: A joint French diabetology and anaesthesiology position statement
E. Cosson, B. Catargi, G. Cheisson, S. Jacqueminet, C. Ichai, A.-M. Leguerrier, A. Ouattara, I. Tauveron, E. Bismuth, D. Benhamou, P. Valensi
Diabetes & Metabolism.2018; 44(3): 200. CrossRef
MicroRNA‐326‐3p ameliorates high glucose and ox‐LDL‐IC‐ induced fibrotic injury in renal mesangial cells by targeting FcγRIII
Yiting Wang, Rui Zhang, Junlin Zhang, Fang Liu
Nephrology.2018; 23(11): 1031. CrossRef
Urinary Extracellular Vesicle
Wei-Cheng Xu, Ge Qian, Ai-Qun Liu, Yong-Qiang Li, He-Qun Zou
Chinese Medical Journal.2018; 131(11): 1357. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes
Eugene Han, Gyuri Kim, Ji-Yeon Lee, Yong-ho Lee, Beom Seok Kim, Byung-Wan Lee, Bong-Soo Cha, Eun Seok Kang
Endocrinology and Metabolism.2017; 32(2): 274. CrossRef
WITHDRAWN: Salvianolate attenuates renal fibrosis in rat models of diabetic nephropathy by inhibiting inflammation and oxidative stress mechanisms
Chongxiang Xiong, Jianrao Lu, Xinhua Wang, Monica V. Masucci
Biochemical and Biophysical Research Communications.2017;[Epub] CrossRef
Diffusion tensor imaging of the renal cortex in diabetic patients: correlation with urinary and serum biomarkers
Ahmed Abdel Khalek Abdel Razek, Mohammad Alsayed Abd Alhamid Al-Adlany, Alhadidy Mohammed Alhadidy, Mohammed Ali Atwa, Naglaa Elsayed Abass Abdou
Abdominal Radiology.2017; 42(5): 1493. CrossRef
Texte 2 : période préopératoire
Gaëlle Cheisson, Sophie Jacqueminet, Emmanuel Cosson, Carole Ichai, Anne-Marie Leguerrier, Bogdan Nicolescu-Catargi, Alexandre Ouattara, Igor Tauveron, Paul Valensi, Dan Benhamou
Anesthésie & Réanimation.2017; 3(3): 218. CrossRef
Global Cardiovascular and Renal Outcomes of Reduced GFR
Bernadette Thomas, Kunihiro Matsushita, Kalkidan Hassen Abate, Ziyad Al-Aly, Johan Ärnlöv, Kei Asayama, Robert Atkins, Alaa Badawi, Shoshana H. Ballew, Amitava Banerjee, Lars Barregård, Elizabeth Barrett-Connor, Sanjay Basu, Aminu K. Bello, Isabela Bensen
Journal of the American Society of Nephrology.2017; 28(7): 2167. CrossRef
Salvia miltiorrhizaLipophilic Fraction Attenuates Oxidative Stress in Diabetic Nephropathy through Activation of Nuclear Factor Erythroid 2-Related Factor 2
Lin An, Mei Zhou, Faiz M. M. T. Marikar, Xue-Wen Hu, Qiu-Yun Miao, Ping Li, Jun Chen
The American Journal of Chinese Medicine.2017; 45(07): 1441. CrossRef
Addition of nonalbumin proteinuria to albuminuria improves prediction of type 2 diabetic nephropathy progression
Jong Ho Kim, Seo Young Oh, Eun Heui Kim, Min Jin Lee, Yun Kyung Jeon, Bo Hyun Kim, Jin Mi Kim, Yong Ki Kim, Sang Soo Kim, In Joo Kim
Diabetology & Metabolic Syndrome.2017;[Epub] CrossRef
Reversal of Early Diabetic Nephropathy by Islet Transplantation under the Kidney Capsule in a Rat Model
Yunqiang He, Ziqiang Xu, Mingshi Zhou, Minmin Wu, Xuehai Chen, Silu Wang, Kaiyan Qiu, Yong Cai, Hongxing Fu, Bicheng Chen, Mengtao Zhou
Journal of Diabetes Research.2016; 2016: 1. CrossRef

First
Prev
Page of 1
Next
Last

Search